Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell

Abstract

transferring a protein, an antibody or another foreign substance into a cell without impairing the function or structure thereof; and methods of transferring a foreign substance into a cell in a time and quantity controllable manner at a high efficiency by using the above-described delivery protein or an envelope virus or inactivated envelope virus in combination with said delivery protein. As the results of intensive studies on a method of enclosing a foreign substance in the envelope of an envelope virus, it is found out that a protein containing a polypeptide having an affinity for a constituent of the envelope virus contributes to the efficient enclosure of the foreign substance in the envelope. Moreover, it is found out that use of the aforementioned protein enables foreign substances to be included in an envelope virus or inactivated envelope virus and therefore the resulting foreign substance-containing envelope virus or inactivated envelope virus makes it possible to efficiently transfer the substances into cells without damaging the physiological function thereof.

Description

FIELD OF THE INVENTION

[0001]The present invention relates to proteins which allow foreign substances to be enclosed within the envelope of envelope viruses or inactivated envelope viruses, and to methods for the introduction of foreign substances into target cells by means of envelope viruses or inactivated envelope viruses into which the foreign substance is incorporated with said protein.

BACKGROUND OF THE INVENTION

[0002]Based on introduction of genes into cells, it is difficult to control the levels of expressed proteins in each cell. Based on function inhibition represented by siRNA and the antisense method, it is also impossible to repress the function of already-expressed proteins. Especially, when a protein has a long half-life, it is hard to expect its inhibitory effects. Therefore, various attempts have been made to introduce proteins and antibodies into cells.

[0003]The known technique for introducing proteins into cells includes methods utilizing cationic liposomes and membrane-permeable peptides. Since the cationic liposome-based delivery performs transfection into cells using charges, it is frequently hard to make preparations because the charge varies from protein to protein, and it is often difficult to perform introduction due to protein charges. The known membrane-permeable peptide-based delivery techniques are those utilizing HIV-derived basic TAT peptides. The reported method of introducing antibodies into cells is a method utilizing a fusion protein consisting of TAT which functions as the membrane-permeable peptide and an antibody-binding region such as Protein A (Patent Document 1). However, the basic membrane-permeable peptide-based introduction of proteins still have problems in scenes wherein intracytoplasmic localization is demanded since basic peptides have nuclear import activity and TAT peptides are known to be transported into the nucleus.

[0004]The microinjection-based introduction of proteins and antibodies into cells needs special machinery and tools and also requires extremely complicated operations.

[0005]Although, on the basis of inactivated envelope virus delivery for introducing substances into cells, it is known that it is possible to introduce a nucleic acid such as a gene (Patent Document 2) and a protein such as RNase Tl and β-Galactosidase (Non-Patent Documents 1 & 2), it is not said to have enough efficiency to introduce antibodies into cells (Non-Patent Documents 3 & 4).

[Patent Document 1] JP 2005-052083, A

[Patent Document 2] US 2003/0013195 A

[Non-Patent Document 1] European Journal Biochemistry vol. 271, No. 17, 3567-3572, 2004

[0006][Non-Patent Document 2] Neurosci. Lett., 378(1), 18-21, 2005 Apr. 11, 2005

[Non-Patent Document 3] Medical Science Digest vol. 29 (3), 38-41, 2003

[Non-Patent Document 4] Current Gene Therapy, vol. 4, 183-194, 2004

SUMMARY OF THE INVENTION

[0007]The present invention provides proteins for introducing one or more proteins, antibodies or other foreign substances (non-self or exogenous substances) into one or more cells without impairing the function, property or structure thereof; and methods of introducing the foreign substance into the cell in a time- and quantity-controllable manner with high efficiency by using the above-described delivery protein or an envelope virus or inactivated envelope virus in combination with said delivery protein.

[0008]The present inventors have conducted an extensive research on methods of enclosing foreign substances within the envelope of envelope viruses. As a result, the present inventors have succeeded in finding that a protein containing a polypeptide having an affinity for (or compatible to) a constituent of the envelope virus contributes to the efficient enclosure of the foreign substance in the envelope.

[0009]Further, the present inventors have succeeded in finding that use of the above-described proteins enables foreign substances to be included in an envelope virus or inactivated envelope virus and the resultant foreign substance-containing envelope viruses or inactivated envelope viruses make it possible to efficiently transfer the substance into cells without damaging the physiological function thereof. Therefore, the present invention has been achieved.

[0010]The present invention provides the following:

[0011][1]A protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell.

[0012][2] The protein according to the above [1], wherein the protein comprising said polypeptide (a) in combination with the polypeptide (b) is a fusion protein.

[0013][3] The protein according to the above [1] or [2], wherein said polypeptide (a) is a polypeptide having an affinity for one or more components existing in the inner space of an envelope.

[0014][4] The protein according to the above [1] or [2], wherein said polypeptide (a) is

[0015](1) a polypeptide of an amino acid sequence of SEQ ID NO: 2,

[0016](2) a polypeptide having an amino acid sequence substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or

[0017](3) a peptide fragment (partial peptide) thereof.

[0018][5] The protein according to the above [1] or [2], wherein said polypeptide (b) is an antibody-binding polypeptide.

[0019][6] The protein according to the above [5], wherein said antibody-binding polypeptide is a polypeptide that can bind to an antibody Fc region or kappa (K) light chain.

[0020][7] The protein according to the above [5], wherein said antibody binding polypeptide is

[0021](1) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51,

[0022](2) a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence (1), or

[0023](3) a peptide fragment (partial peptide) thereof.

[0024][8] A DNA encoding a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components and a polypeptide capable of binding to an antibody wherein said fusion protein is a polypeptide selected from the group consisting of: [0025](1) a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof, [0026](2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and [0027](3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

[0028][9] An envelope virus or inactivated envelope virus containing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell.

[0029][10] The envelope virus or inactivated envelope virus according to the above [9], wherein said virus contains a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components and an antibody-binding polypeptide wherein said fusion protein is a polypeptide selected from the group consisting of: [0030][1] a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof, [0031](2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and [0032](3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

[0033][11] An envelope virus or inactivated envelope virus containing a complex constituted of (i) a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, and (ii) one or more foreign substances.

[0034][12] The envelope virus or inactivated envelope virus according to the above [11], wherein said foreign substance is an antibody.

[0035][13] The envelope virus or inactivated envelope virus according to the above [12], wherein said virus contains a complex constituted of

[0036](i) a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components, fused to an antibody binding polypeptide, and

[0037](ii) an antibody,

wherein said fusion protein is a polypeptide selected from the group consisting of: [0038](1) a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof, [0039](2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and [0040](3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

[0041][14] A process for preparing an envelope virus or inactivated envelope virus containing a foreign substance within an envelope, which comprises the steps consisting of [0042](1) mixing an envelope virus or inactivated envelope virus with a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, [0043](2) subjecting the resultant mixture from the above step (1), to a treatment affecting the permeability of envelopes, and [0044](3) mixing the resultant product from the above step (2), with one or more foreign substances.

[0045][15] A process for preparing an envelope virus or inactivated envelope virus containing a foreign substance within an envelope, which comprises the steps consisting of [0046](1) mixing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, with one or more foreign substances to form a complex, [0047](2) mixing the resultant mixture from the above step (1), with an envelope virus or inactivated envelope virus, and [0048](3) subjecting the resultant mixture from the above step (2), to a treatment affecting the permeability of envelopes.

[0049][16] The process according to the above [14] or [15], wherein the protein comprising said polypeptide (a) in combination with the polypeptide (b) is a fusion protein.

[0050][17] The process according to the above [14] or [15], wherein said foreign substance is an antibody.

[0051][18] A method for introducing one or more foreign substances into a cell with an envelope virus or inactivated envelope virus, which comprises the steps consisting of [0052](1) mixing an envelope virus or inactivated envelope virus with a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, [0053](2) subjecting the resultant mixture from the above step (1), to a treatment affecting the permeability of envelopes, [0054](3) mixing the resultant product from the above step (2) with one or more foreign substances, and [0055](4) contacting the resulting foreign substance-containing envelope virus or inactivated envelope virus from the above step (3), with one or more cells.

[0056][19] A method for introducing one or more foreign substances into a cell with an envelope virus or inactivated envelope virus, which comprises the steps consisting of [0057](1) mixing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, with one or more foreign substances to form a complex, [0058](2) mixing the resultant mixture from the above step (1), with an envelope virus or inactivated envelope virus, [0059](3) subjecting the resultant mixture from the above step (2), to a treatment affecting the permeability of envelopes and [0060](4) contacting the resulting foreign substance-containing envelope virus or inactivated envelope virus from the above step (3), with one or more cells.

[0061][20] The process according to the above [18] or [19], wherein the protein comprising said envelope viral component-affinity polypeptide (a) in combination with the foreign substance-binding polypeptide (b) is a fusion protein.

[0062][21] The process according to the above [18] or [19], wherein said foreign substance is an antibody.

[0063][22] A complex composed of (i) a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, and (ii) one or more foreign substances to be introduced into one or more cells.

ADVANTAGEOUS PROFILES OF THE INVENTION

[0064]In accordance with the present invention, proteins, antibodies and other foreign substances (non-self or exogenous substances) can be introduced into cells via simple operations without damaging their function, property and structure. When the foreign substance is an antibody, a variety of substances bound to the antibodies can be transferred into cells. Antibodies against various intracellular materials can also be introduced and the function of such intracellular materials can be regulated. Further, antibodies against substances to be administered from the outside of cells as well as metabolites thereof and others can be introduced and therefore the intracellular physiological activity of said substance can also be regulated.

[0065]The above objects and other objects, features, advantages, and aspects of the present invention are readily apparent to those skilled in the art from the following disclosures. It should be understood, however, that the disclosures in the specification including the following best modes of carrying out the invention, examples, and others are illustrating preferred embodiments of the present invention and given for purposes of illustration only. It will become apparent to the skilled in the art that a great number of variations and/or alterations (or modifications) of this invention may be made based on knowledge from the disclosure in the following parts and other parts of the specification without departing from the spirit and scope thereof as disclosed herein. All of the patent publications and reference documents cited herein for illustrative purposes are hereby incorporated by reference into the present disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

[0066]FIG. 1 shows SDS-PAGE patterns for ZZ-NP-containing inactivated HVJ envelope (lane 2), inactivated HVJ envelope alone (lane 1), ZZ-NP alone (lane 3), and molecular markers (lane 4).

[0067]FIG. 2 shows Western blotting patterns for mouse IgG-containing inactivated HVJ envelopes. Lane 4 to 6: mouse IgG enclosed within ZZ-NP-containing inactivated HVJ envelopes. Lane 1 to 3: mouse IgG Ab alone (1/3 μg, 1 μg, and 3 μg, respectively).

[0068]FIG. 3 shows photos for Anti-NPC (Nuclear Pore Complex) antibody, incorporated into HeLa S3 cell with inactivated HVJ envelope and, stained with Alexa 488-labeled goat Anti-Mouse IgG F(ab')₂ fragment. Fluorescence image (1). Bright-field image (2).

[0069]FIG. 4 shows Western blotting patterns for mouse IgG antibody-containing inactivated HVJ envelopes. Mouse IgG antibodies incorporated into inactivated HVJ envelopes (lane 1, 2). Mouse IgG antibodies incorporated into inactivated HVJ envelopes containing the proteins of the present invention (ZZ-NP: lane 3, 4; ZZ-NPK1: lane 5, 6; ZZ-NPK2: lane 7, 8, ZZ-NPK3: lane 9, 10; ZZ-NPK4: lane 11, 12). Lane 13 to 17: Mouse IgG Ab alone ( 1/16 μg, 1/8 μg, 1/4 μg, 1/2 μg, and 1 μg, respectively).

[0070]FIG. 5 shows photos for Anti-NPC (Nuclear Pore Complex) Ab, incorporated into HeLa S3 cell with inactivated HVJ envelope and, stained with Alexa 488-labeled goat Anti-Mouse IgG F(ab')₂ fragment. Cells receiving introduction of Anti-NPC Ab with ZZ-NPK1-containing inactivated HVJ envelopes (1). Cells receiving introduction with Anti-NPC Ab alone (2).

[0071]FIG. 6 shows SDS-PAGE patterns for inactivated HVJ envelopes within which G-NPK1 or GG-NPK1 made Rat IgG2b Ab be enclosed. Rat IgG2b Ab incorporated into inactivated HVJ envelopes containing the proteins of the present invention (G-NPK1: 6, GG-NPK1: 9). Molecular markers (lane 1). Rat IgG2b Ab alone (lane 2). Inactivated HVJ envelope alone (lane 3). G-NPK1 alone (lane 4). GG-NPK1 alone (lane 7). Inactivated HVJ envelopes containing the proteins of the present invention (G-NPK1: lane 5, GG-NPK1: lane 8).

[0072]FIG. 7 shows SDS-PAGE patterns for inactivated HVJ envelopes within which L-NPK1 or LL-NPK1 made Rat IgG2b Ab be enclosed. Rat IgG2b Ab incorporated into inactivated HVJ envelopes containing the proteins of the present invention (L-NPK1: 6, LL-NPK1: 9). Molecular markers (lane 1). Rat IgG2b Ab alone (lane 2). Inactivated HVJ envelope alone (lane 3). L-NPK1 alone (lane 4). LL-NPK1 alone (lane 7). Inactivated HVJ envelopes containing the proteins of the present invention (L-NPK1: lane 5, LL-NPK1: lane 8).

[0073]FIG. 8 show photos for Rat IgG2b Ab, incorporated into HeLa S3 cells with inactivated HVJ envelope and, stained with Alexa 488-labeled chicken anti-Rat IgG Ab. Cells receiving introduction of Rat IgG2b Ab with inactivated HVJ envelopes containing the proteins of the present invention [(G-NPK1: (1), GG-NPK1: (2), L-NPK1: (3), LL-NPK1: (4)]. Cells receiving introduction with rat IgG2b Ab alone (5).

[0074]FIG. 9 shows the detection, with Alexa 488-labeled goat anti-mouse IgG F(ab')₂ fragments, of anti-NPC (Nuclear Pore Complex) antibodies introduced into HeLa S3 cells with inactivated HVJ envelopes. Cells treated by G-NPK1- or GG-NPK1-containing inactivated HVJ envelope-mediated introduction of anti-NPC Ab [(1): G-NPK1, (2): GG-NPK1]. (3): Cells treated by introduction of anti-NPC Ab alone.

BEST MODES OF CARRYING OUT THE INVENTION

[0075]The envelope viruses that can be used herein include a variety of viruses as long as they have an envelope. It is known that the envelope virus delivers nucleic acid molecules, nucleocapsid proteins and others into host cells. Such viruses include those belonging to a viral family selected from the group consisting of Retroviridae, Togaviridae, Coronaviridae, Flaviviridae, Paramyxoviridae, Orthomyxoviridae, Bunyaviridae, Rhabdoviridae, Poxyiridae, Herpesviridae, Baculoviridae and Hepadnaviridae. Preferable viruses are those in the family Paramyxoviridae or Orthomyxoviridae, more preferably Paramyxoviridae. Still more preferred viruses are those belonging to the subfamily Paramyxovirinae. The virus of the Paramyxovirinae includes those of the genus Respirovirus, the genus Rubulavirus, and the genus Morbillivirus. Among them, viruses of the genus Respirovirus are preferable, more preferably Sendai virus. The terms "Sendai virus" and "HVJ" (Hemagglutinating virus of Japan) are interchangeably used herein.

[0076]The "inactivated" as used herein refers to inactivation of genomes when stated in connection with viruses. The inactivated virus is replication-defective. The genome inactivation can be achieved by, for example, UV or alkylating agent treatments. Any of envelope viruses and inactivated envelope viruses can be used herein, and the inactivated envelope viruses are more desirable. The phrases inactivated envelope viruses and inactivated viral envelopes are interchangeably used herein.

[0077]The inventive proteins are those each comprising (a) a polypeptide having an affinity for (compatible to) one or more envelope viral components (or viral constituents) in combination with (b) a polypeptide capable of binding to one or more foreign substances (or exogenous molecules) to be introduced (or transferred) into one or more cells. The polypeptide (a) is a polypeptide facilitating, through binding to the polypeptide (b), the state wherein said foreign substance is "enclosed within an envelope" or "incorporated into the inner space of an envelope". The polypeptide (a) is also a polypeptide elevating the level of said foreign substance enclosed within the envelope. The aforementioned polypeptides (a) and (b) may be in the form of a complex wherein each polypeptide (a) is interacted with each polypeptide (b) to form a subunit, or in the form of a single fusion protein. The fusion proteins are more desirable.

[0078]The "envelope" as used herein refers to a lipid bilayer-based membrane (or membranous structure) which surrounds the nucleocapsid existing in the envelope virus. The phrase, a specific substance (or specific molecule) is "enclosed within an (or the) envelope", means that such a specific substance (or specific molecule) is present in an aqueous phase with which the inner space surrounded by the aforementioned lipid bilayer-based membranous structure is filled up, and/or, in the lipid of the membranous structure, being considered to be dependent on the surface properties (such as hydrophilicity or hydrophobicity) of proteins or foreign substances to be transferred into cells. It is desired that said substances are placed mainly in the aqueous layer inside the envelope of the inactivated virus. Further, the "incorporated in the envelope" as used herein means that a substance becomes "enclosed within the envelope" as aforementioned.

[0079]The above-described envelope viral components include proteins existing on or in the surface of the envelope, phosphorylated (P) proteins, matrix (M) proteins, nucleic acids, proteins associated with the nucleic acid, etc. Embodiments of the above-described polypeptide (a) are proteins, or peptide fragments thereof, which have an affinity for (or are compatible to) one or more members selected from the group consisting of proteins existing on or in the surface of the envelope, phosphorylated proteins, matrix proteins, nucleic acids, and proteins associated with the nucleic acid. Preferably, the above-described polypeptide (a) is a protein, or a peptide fragment thereof, which is compatible to (or has an affinity for) one or more virus components existing in the inside of the envelope, more preferably a protein, or a peptide fragment thereof, which has an affinity for (or is compatible to) one or more members selected from the group consisting of the phosphorylated protein, the matrix protein, the nucleic acid, and the protein associated with the nucleic acid. A more preferred embodiment of the polypeptide (a) is an envelope viral nucleocapsid protein, or a peptide fragment thereof.

[0080]The nucleocapsid protein (abbreviated to "NP"), derived from Sendai virus which is a preferred example of the envelope virus, has an affinity for the protein existing in the inside of the virus envelope and the virus nucleic acid (RNA). The NP has also an affinity for interactions between the nucleocapsid proteins and allows the formation of complexes within the virus wherein the NP is closely associated with the nucleic acid. The Sendai virus nucleocapsid protein includes preferably polypeptides of an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence substantially identical thereto, or peptide fragments (partial peptides) thereof. The peptide fragments are those each having an amino acid sequence selected from SEQ ID NOs: 27, 29, 31, and 33.

[0081]The above described (b) polypeptide capable of binding to one or more foreign substances (foreign substance-binding polypeptide (b)) may be any as long as it is a polypeptide comprising an amino acid sequence capable of binding to the foreign substance, and can be suitably selected, depending on the foreign substances to be treated. The foreign substance to be transferred into one or more cells includes nucleic acid molecules, proteins, polysaccharides and lipids, preferably proteins, and more preferably antibodies. For instance, when the foreign substance is nucleic acid, the polypeptide (b) includes basic amino acid-rich polypeptides, polypeptides which can bind to the specific sequence of genes and others. Embodiments of such polypeptides are DNA-binding sequences such as GAL4. When the foreign substances are materials labeled with a biotin-related molecule having an imidazoline ring, the polypeptide (b) includes avidins such as egg white-derived avidin, and streptavidin derived from bacteria. When the foreign substances are antibodies, the polypeptide (b) includes polypeptides capable of binding to an antibody (Ab) (antibody-binding polypeptides) or peptide fragments thereof. Desirable embodiments of the Ab-binding polypeptide are immunoglobulin-binding proteins and peptide fragments thereof. More preferable examples of the antibody-binding polypeptide are proteins capable of binding to an antibody Fc region or kappa (κ) light chain and peptide fragments thereof. These proteins or peptide fragments thereof can be suitably selected depending on antibodies to be bound. Where the antibody (Ab) is a single-chain antibody or a molecule wherein the variable domains of the light and heavy chains are joined by a flexible peptide linker, κ light chain-binding molecules will be selected. More specifically, they include Fc region-binding molecules, Protein A, Protein G, and Protein A/G; κ light chain-binding molecules, Protein L; amino acid sequences substantially identical thereto or peptide fragments thereof. These immunoglobulin-binding proteins used herein may be whole protein units, or immunoglobulin-binding sequence fragments of such proteins. It is desirable that the aforementioned binding sequences are amino acid sequences which bind to an Fc region or κ light chain. The Fc region-binding sequence includes amino acid sequences for the A, B, C, D, and E regions of Protein A, said B region-derived Z region, and the C1, C2, and C3 regions of Protein G, and amino acid sequences substantially identical thereto. It is possible to use the member of such species alone or in combination with one or more sequences selected from the aforementioned sequences. More desirable examples thereof are the Z region having an amino acid sequence of SEQ ID NO: 4, the Protein G C1 region having an amino acid sequence of SEQ ID NO: 49, the Protein L B1 region having an amino acid sequence of SEQ ID NO: 51, and amino acid sequences substantially identical thereto.

[0082]As above-described, the polypeptide (a) may be joined with the polypeptide (b) to form a fusion protein. Alternatively, they may be in the form of a complex wherein each polypeptide (a) is associated with each polypeptide (b) to form a subunit. The fusion proteins are more preferable. Such fusion proteins are molecules each comprising (a) the polypeptide having an affinity for one or more envelope viral components in combination with (b) the foreign substance-binding polypeptide, as aforementioned, wherein the polypeptide (b) may be positioned at either the N-terminal end (amino-terminal side) or the C-terminal end (carboxyl-terminal side) of the polypeptide (a). More desirable embodiments are fusion proteins wherein the polypeptide (b) is positioned at the N terminal end of the polypeptide (a). The fusion protein may contain a spacer region between the polypeptides (a) and (b) for avoiding interference due to steric hindrance. The spacer region may be a glycine spacer, or composed of glycine and serine.

[0083]More specific embodiments of the fusion proteins include the following: [0084](1) molecules each comprising a basic amino acid-rich polypeptide at the N-terminal end of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence substantially identical thereto. [0085](2) molecules each comprising a DNA-binding sequence, such as GAL4, at the N-terminal end of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence substantially identical thereto. [0086](3) molecules each comprising any amino acid sequence of avidins at the N-terminal end of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence substantially identical thereto. [0087](4) molecules each comprising an antibody-binding protein or a peptide fragment thereof at the N-terminal end of the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence substantially identical thereto.

[0088]Preferable examples of the fusion protein molecule (4) are proteins each comprising an amino acid sequence of SEQ ID NO: 6, 13, 15, 17, 19, 53, 55, 57 or 59, or an amino acid sequence substantially identical thereto, more preferably proteins each comprising an amino acid sequence of SEQ ID NO: 6, 13, 55 or 59, or an amino acid sequence substantially identical thereto.

[0089]The phrase "amino acid sequence substantially identical" as used herein refers to amino acid sequences that have at least about 70%, preferably about 80%, more preferably about 90%, most preferably about 95% or higher amino acid residue identity (or homology).

[0090]As used herein, the term "identity" or "homology" means the percentage (%) of identical amino acid and similar amino acid residues as compared to all overlapped amino acid residues in optimal alignment of two amino acid sequences, when aligned using one of mathematical algorithms known in the art (preferably, said algorithm can take into account the presence of gaps, which need to be introduced into one or both sequences for the optimal alignment). The "similar amino acid" refers to amino acids of like characteristics (e.g., physical and chemical properties), which include those classified into the same group, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), hydroxyl group-containing amino acids (Ser, Thr), and small-sized side chain amino acids (Gly, Ala, Ser, Thr, Met). Replacements among such similar amino acids will be likely to be phenotypically silent in a protein (i.e., conservative amino acid substitutions). Embodiments of the conservative amino acid substitution are well known in the art and found in a variety of documents (see, for instance, Bowie et al., Science, 247: 1306-1310 (1990)).

[0091]An example of algorithm that is suitable for determining amino acid sequence homology is the algorithm described in Karlin et al., Proc. Natl. Acad. Sci. USA, 90: 5873-5877 (1993), but not limited to.

[0092]Preferred examples of the "protein comprising an amino acid sequence substantially identical thereto" herein are proteins that are substantially identical in both amino acid sequence levels and qualitative activities, and the like.

[0093]The proteins according to the present invention encompass modified proteins (so-called "muteins") comprising any of (1) deleted amino acid sequences which have one or more deletions of one or more amino acid residues (preferably about 1 to 30, still preferably about 1 to 10, and further preferably several (1 to 5) amino acid residues); (2) added amino acid sequences which have one or more additions of one or more amino acid residues (preferably about 1 to 30, still preferably about 1 to 10, and further preferably several (1 to 5) amino acid residues); (3) inserted amino acid sequences which have one or more insertions of one or more amino acid residues (preferably about 1 to 30, still preferably about 1 to 10, and further preferably several (1 to 5) amino acid residues); (4) substituted amino acid sequences which have one or more substitutions of one or more amino acid residues (preferably about 1 to 30, still preferably about 1 to 10, and further preferably several (1 to 5) amino acid residues) with one or more other amino acid residues; and (5) combinations wherein the aforementioned one or more amino acid deletions, additions, insertions and substitutions are associated one another. Where the amino acid sequence is inserted, deleted or substituted as aforementioned, a position modified by the insertion, deletion, or substitution is not limited to, as long as the resultant modified molecule retains the activity of the unmodified protein.

[0094]Herein, protein or peptide sequences are written in the N-terminal end to C-terminal end direction from left to right according to the conventional peptide notation. The protein of the present invention is any of molecules having a carboxyl (--COOH), carboxylate (--COO.sup.-), amide (--CONH₂) or ester (--COOR) group at the C-terminal end. For the ester used herein, R is a C_1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; a C_3-8 cycloalkyl group such as cyclopentyl and cyclohexyl; a C_6-12 aryl group such as phenyl and α-naphtyl; a C_7-14 aralkyl group including a phenyl-C_1-2 alkyl group such as benzyl and phenethyl, and an α-naphtyl-C_1-2 alkyl group such as α-napthylmethyl; a pivaloyloxymethyl group, etc. When the protein of the present invention has a carboxyl (or carboxylate) group at a site other than the C-terminal end, protein molecules wherein the carboxyl group is amidated or esterified are also included therein. In such cases, the ester as used herein is selected from those listed in connection with the aforementioned C-terminal end ester. Further, the proteins of the present invention also encompass protein molecules wherein the amino group of the N-terminal amino acid residue is protected with a protective group (for example, C_1-6 acyl including C_1-6 alkanoyl such as formyl and acetyl), those molecules wherein the N-terminal glutamine residue generated through in vivo cleavage is pyroglutamated, those molecules wherein a substituent on an intermolecular amino acid side chain (e.g., --OH, --SH, an amino group, an imidazole group, an indole group, a guanidino group and the like) is protected with a suitable protective group (e.g., C_1-6 acyl including C_1-6 alkanoyl such as formyl and acetyl), conjugated proteins such as so-called glycoproteins having one or more saccharide chains.

[0095]The subject protein-encoding DNA includes, for example, DNA molecules having a nucleotide sequence of SEQ ID NO: 5, 12, 14, 16, 18, 48, 50, 52, 54, 56 or 58, or DNA molecules that not only have a nucleotide sequence capable of hybridizing to said nucleotide sequence under high-stringent conditions but also encode a protein with the substantially same nature of activity, and others. The DNA molecule, used herein, that is capable of hybridizing to said nucleotide sequence under high-stringent conditions includes DNA comprising a nucleotide sequence with at least about 50%, preferably at least about 6.0%, more preferably at least about 70%, particularly preferably at least about 80%, most preferably at least about 90% or higher homology to said nucleotide sequence. The hybridization can be performed according to methods known per se or equivalent techniques, for instance, the method disclosed in J. Sambrook et al., Molecular Cloning, Second Edition, Cold Spring Harbor Lab. Press, 1989, etc. When commercially available libraries are used, the hybridization can be carried out according to methods described in manuals attached thereto. Preferably, the hybridization can be achieved under high-stringent conditions. High-stringent hybridization conditions referred to herein are conditions in about 19 to 40 mM, preferably about 19 to 20 mM, sodium salt at about 50 to 70° C., preferably about 60 to 65° C. Particularly, preferable high-stringent conditions are those in about 19 mM sodium salt at about 65° C.

[0096]DNA sequences can be converted with any of known kits including, for instance, Mutan®-Super Express Km (Takara Shuzo, Tokyo, Japan), Mutan®-K (Takara Shuzo, Tokyo, Japan) and other kits, based on methods known per se, such as ODA-LA PCR method, Gapped duplex method, and Kunkel method, or equivalent techniques. Cloned DNA can be used without any modification, or after, as desired, digestion with restriction enzymes and/or addition of linkers, depending on targeted subjects. The DNA may include the ATG translation initiation codon at the 5'-end and the translation stop codon, TAA, TGA or TAG, at the 3'-end. These translation initiation and stop codons can be added using suitable synthetic DNA adaptors.

[0097]Expression vectors that comprise DNA coding for a protein within the scope of the present invention can be constructed, for example, as follows: a DNA molecule that encodes the protein of the present invention is cut to give a target DNA fragment which is then inserted into a suitable expression vector downstream of a promoter in the vector. The expression vector used herein includes E. coli-derived plasmids (e.g., pBR322, pBR325, pUC12, pUC13, and pET28a); Bacillus subtilis-derived plasmids (e.g., pUB110, pTP5, and pC194); yeast-derived plasmids (e.g., pSH19, and pSH15); insect cell expression plasmids (e.g., pFast-Bac); animal cell expression plasmids (e.g., pA1-11, pXT1, pRc/CMV, pRc/RSV, and pcDNAI/Neo); bacteriophages such as λ phage; insect viral vectors such as baculoviral vectors (e.g., BmNPV, and AcNPV); viral vectors derived from animal viruses such as retro-viruses, vaccinia viruses, and adeno-viruses.

[0098]Any promoter may be employed as long as it serves as a suitable promoter for hosts used in gene expression. When hosts are animal cells, examples of such promoters used herein are the SRα promoter, the SV40 or LTR promoter, the CMV (cytomegalovirus) and RSV (Rous sarcoma virus) promoters, MoMuLV (Moloney murine leukemia virus) LTR, the herpes simplex virus thymidine kinase promoter (HSV-TK), etc. Among them, the CMV promoter, the SRα promoter and the like are preferable.

[0099]When hosts are members of the genus Escherichia, trp promoter, lac, recA, λ_PL, lpp, T7 promoters and others are preferable. When hosts are members of the genus Bacillus, SPO1, SPO2, penP promoters and others are preferable. When hosts are yeast members, PHO5, PGK, GAP, ADH promoters and others are preferred. For insect host cells, the polyhedrin promoter, the P10 promoter and others are preferable.

[0100]The expression vector which can be used herein includes, in addition to the above, those comprising, if desired, an enhancer, a polyadenylation signal, a selectable marker, the SV40 origin of replication (hereinafter, often abbreviated to SV40 ori) and the like. The selectable marker includes, for example, a dihydrofolate reductase gene (hereinafter, often abbreviated to dhfr, resistant to methotrexate (MTX)), ampicillin-resistant gene (hereinafter, often abbreviated to ampr), neomycin-resistant gene (hereinafter, often abbreviated to neor, resistant to G418) and others. Particularly, when dhfr gene-deficient Chinese hamster cells are used together with the dhfr gene as a selectable marker, the target gene may also be selected with a thymidine-free medium. If necessary, a nucleotide sequence coding for a signal sequence (signal codons) suitable for a host may be added to the 5'-terminal side of DNA encoding the protein or peptide fragment according to the present invention (or the native signal codons may be replaced with signal codons compatible with the host). For example, a PhoA signal sequence, an OmpA signal sequence, or the like, can be used for Escherichia sp. hosts; an α-amylase signal sequence, a subtilisin signal sequence, or the like, for Bacillus sp. hosts; an MFα signal sequence, a SUC2 signal sequence, or the like, for yeast hosts; and an insulin signal sequence, an α-interferon signal sequence, an antibody molecule signal sequence, or the like, for animal cell hosts, respectively.

[0101]The Escherichia sp. used herein includes, for example, Escherichia coli K12•DH1 [Proc. Natl. Acad. Sci. USA, Vol. 60, 160 (1968)], Escherichia coli JM103 [Nucleic Acids Research, Vol. 9, 309 (1981)], Escherichia coli JA221 [Journal of Molecular Biology, Vol. 120, 517 (1978)], Escherichia coli HB101 [Journal of Molecular Biology, Vol. 41, 459 (1969)], Escherichia coli C600 [Genetics, Vol. 39, 440 (1954)], and Escherichia coli Rosetta (DE3) [Novagen]. The Bacillus sp. used herein includes, for example, Bacillus subtilis MI114 [Gene, Vol. 24, 255 (1983)], Bacillus subtilis 207-21 [Journal of Biochemistry, Vol. 95, 87 (1984)]. The yeast used herein includes, for example, Saccharomyces cerevisiae AH22, AH22R.sup.-, NA87-11A, KDK-5D, 20B-12, Schizosaccharomyces pombe NCYC1913, NCYC2036, and Pichia pastoris KM71. The insect cells used herein include, for example, when a virus is AcNPV, established insect cell lines, Spodoptera frugiperda cells (Sf cells), derived from a larva of cabbage army worm (Spodoptera frugiperda), MG1 cells, derived from the midgut of Trichoplusia ni, High Five® cells, derived from an egg of Trichoplusia ni, cells derived from Mamestra brassicae, cells derived from Estigmena acrea and others. When a virus is BmNPV, the insect cells used herein are established cell lines derived from silkworm (Bombyx mori N cells; BmN cells) and the like. Examples of the Sf cells used herein are Sf9 cells (ATCC CRL1711), and Sf21 cells (both, Vaughn, J. L. et al., In Vivo, 13, 213-217 (1977)). Examples of the insects used herein are silkworm larva [Maeda et al., Nature, Vol. 315, 592 (1985)] and the like.

[0102]The animal cells used herein include, for example, monkey COS-7 cell lines, monkey Vero cells, Chinese hamster ovary (CHO) cells (hereinafter, abbreviated to CHO cells), dhfr gene-deficient Chinese hamster cell CHO (hereinafter, abbreviated to CHO(dhfr.sup.-) cell), mouse L cells, mouse AtT-20 cells, mouse myeloma cells, rat GH3 cells, human FL cells and other cells.

[0103]Transformation (transfection) can be performed according to known methods, depending on a variety of hosts. Escherichia sp. bacteria can be transformed according to the methods disclosed in, for example, Proc. Natl. Acad. Sci. USA, Vol. 69, 2110 (1972) and Gene, Vol. 17, 107 (1982). Bacillus sp. bacteria can be transformed according to the methods disclosed in, for example, Molecular & General Genetics, Vol. 168, 111 (1979). Yeast cells can be transformed according to the methods disclosed in, for example, Methods in Enzymology, Vol. 194, 182-187 (1991); Proc. Natl. Acad. Sci. USA, Vol. 75, 1929 (1978) and others. Insect cells and insects can be transformed according to the method disclosed in, for example, Bio/Technology, Vol. 6, 47-55 (1988). Animal cells can be transformed according to the methods disclosed in, for example, Saibo Kougaku Bessatsu 8 Shin-Saibo Kougaku Jikken Purotokoru (Cell Technology Separate Volume 8 Novel Experimental Protocols for Cell Technology), 263-267 (1995, Shujunsha Co., Ltd., Tokyo, Japan), and Virology, Vol. 52, 456 (1973).

[0104]Cultivation of transformants or transfectants can be performed according to conventional techniques depending on a variety of hosts. For example, the transformant (transfectant) in which the host is Escherichia sp. or Bacillus sp. can be cultivated suitably in a liquid culture medium. A preferred culture medium may contain carbon sources, nitrogen sources, minerals, and other elements, necessary for growing the transformant. The carbon source may include, for example, glucose, dextrin, soluble starch, sucrose, etc. The nitrogen source may include, for example, organic or inorganic substances such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, soybean-cakes, potato extracts. Examples of the minerals are calcium chloride, sodium dihydrogen phosphate, magnesium chloride, etc. It may also be supplemented with yeast extracts, vitamins, growth promoting factors, etc. The pH of the medium is desirably about 5 to 8. A preferable example of the medium for culturing transformants wherein the host is Escherichia sp. is an M9 medium containing glucose and casamino acid (Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York 1972). If necessary, the medium may be supplemented with a drug such as 3β-indolyl acrylic acid in order to make a promoter work efficiently. When the host is Escherichia sp., the transformant is usually cultured at about 15 to 43° C. for about 3 to 24 hr. If necessary, aeration and stirring may be optionally applied.

[0105]When the host is Bacillus sp., the transformant is usually cultured at about 30 to 40° C. for about 6 to 24 hr. If necessary, aeration and stirring may be optionally applied.

[0106]When the host is yeast, examples of the medium for culturing the transformant are Burkholder minimum medium [Bostian, K. L. et al., Proc. Natl. Acad. Sci. USA, Vol. 77, 4505 (1980)], SD medium containing 0.5% casamino acid [Bitter, G. A. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 5330 (1984)], and others. The pH of the medium is desirably about 5 to about 8. Culturing is performed usually at about 20° C. to 35° C. for about 24 to 72 hr. If necessary, aeration and stirring may be optionally applied.

[0107]The medium used herein for culturing the transformant whose host is an insect cell or insect includes, for example, Grace's Insect Medium [Grace, T. C. C., Nature, Vol. 195, 788 (1962)] appropriately supplemented with an additive such as 10% inactivated bovine serum. The pH of the medium is desirably about 6.2 to 6.4. Cultivation is usually carried out at about 27° C. for about 3 to 5 days. If necessary, aeration and stirring may be optionally applied.

[0108]The medium used herein for culturing the transformant whose host is an animal cell includes, for example, about 5 to 20% fetal bovine serum-containing minimum essential medium (MEM) [Science, Vol. 122, 501 (1952)], Dulbecco's modified Eagle's medium (DMEM) [Virology, Vol. 8, 396 (1959)], RPMI 1640 medium (The Journal of the American Medical Association, Vol. 199, 519 (1967)), 199 medium [Proceeding of the Society for the Biological Medicine, Vol. 73, 1 (1950)] and others. The pH of the medium is desirably about 6 to 8. Cultivation is usually carried out at about 30° C. to 40° C. for about 15 to 60 hr. If necessary, aeration and stirring may be optionally applied.

[0109]The protein of the present invention can be extracted, isolated and/or purified from the resulting culture of said transformant according to methods known per se. For example, when the proteins of the present invention are extracted from cultured bacteria or cell cytoplasms, the following techniques are appropriately used: the bacteria or cells are collected by a known method, next suspended in a suitable buffer, and then disrupted by sonication, lysozyme digestion and/or freeze-thawing, followed by centrifugation or filtration to afford a crude soluble protein extract. Other conventional extraction or isolation methods can also be applied. The buffer may contain a protein-denaturing agent such as urea or guanidine hydrochloride, or a detergent such as Triton X-100. When the proteins of the present invention are extracted from the membrane fraction, the following processes are used: the bacteria or cells are disrupted in the same manner as aforementioned, and centrifuged at low speed to remove precipitated cell debris. The resultant supernatant is then centrifuged at high speed to precipitate a cell membrane-containing fraction (if necessary, the cell membrane fraction may be purified by density gradient centrifugation). When the proteins of the present invention are secreted outside of the microorganism (cell), culture supernatants are separated from the culture by centrifugation or filtration, and the resulting supernatants are collected.

[0110]The protein of the present invention contained in the resultant soluble fraction, membrane fraction or culture supernatant can be separated, isolated and/or purified according to methods known per se. Such techniques used herein include methods of utilizing solubility such as salting-out and solvent precipitation; methods of utilizing mainly differences in molecular size such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis (SDS-PAGE); methods of utilizing differences in electrical charge such as ion exchange chromatography; methods of utilizing specific affinity such affinity chromatography; methods of utilizing hydrophobic differences such as reversed-phase high-performance liquid chromatography (HPLC); methods of utilizing different isoelectric points such as isoelectric focusing; and other methods. These methods can be appropriately combined.

[0111]When the protein or peptide is in a free form, it can be converted into its salt by methods known per se or modifications thereof. When the protein or peptide is obtained in the form of a salt, it can be converted into the free form or the form of another salt by methods known per se or modifications thereof.

[0112]The protein of the present invention produced by the transformant may be subjected to treatment with a suitable protein-modifying enzyme, before or after purification, to modify it appropriately or to partly remove a polypeptide fragment. Examples of the protein-modifying enzyme used herein include trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, and glycosidase. The presence of the resultant protein of the present invention is determined by enzyme immunoassay or western blot with a specific antibody.

[0113]Further, the protein of the present invention can be in vitro synthesized using, as a template, RNA corresponding to DNA coding for said protein in a cell-free protein translation system selected from the group consisting of rabbit reticulocyte lysate, wheat germ lysate, and others. Alternatively, it can be synthesized using, as a template, DNA coding for the protein of the present invention in a cell-free transcription/translation system containing RNA polymerase.

[0114]The resultant proteins, peptide fragments thereof, antibodies and other molecules obtained herein can also be labeled, if necessary. Labeling techniques are not limited to as long as they are conventionally known methods, but include preferably fluorescent labels, autoradiography, electron-dense materials, and insoluble pigment producing enzymes. Preferably, the labeling is a method of covalently binding with a fluorescent label. Fluorescent substances to be used for the fluorescent label are not limited to, but include, for example, compounds having a fluorescent group such as pyrene, an anthraniloyl group, a dansyl group, fluorescein, rhodamine, and a nitrobenzoxadiazol group. The compounds having the aforementioned fluorescent group are well known (see, for example, HIRATSUKA Toshiaki, "Tanpakushitsu Kakusan Kozo" (Protein Nucleic Acid and Enzyme), Vol. 42, No. 7 (1997), etc.), and can be incorporated into a protein molecule or peptide according to conventional methods.

[0115]The method of incorporating a foreign substance (non-self substance) into the envelope of an envelope virus or inactivated envelope virus with the protein of the present invention comprises the steps consisting of:

[0116]incorporating the protein of the present invention into the envelope, and then contacting the foreign substance (non-self substance) with the above-described virus or inactivated virus; or

[0117]forming a complex consisting of the protein of the present invention and the foreign substance (non-self substance), and then incorporating the resultant complex into the envelope of said virus or inactivated virus.

[0118]1. In the case where the protein of the present invention is incorporated into the envelope virus, followed by contacting the resulting virus with the foreign substance (non-self substance), foreign substance-containing envelope viruses and inactivated envelope viruses can be obtained by the steps consisting of:

[0119](1) mixing the envelope virus or inactivated envelope virus with a protein containing (a) a polypeptide having an affinity for an envelope viral component and (b) a polypeptide having the ability to bind to the foreign substance to be incorporated into a cell,

[0120](2) subjecting the resultant mixture from the above step (1) to a treatment affecting the permeability of the envelope, and

[0121](3) mixing the resultant product from the above step (2) with the foreign substance.

[0122]2. In the case where the protein of the present invention is admixed with the foreign substance (non-self substance) to form a complex, followed by incorporating the resultant complex into the envelope virus or inactivated envelope virus, foreign substance-containing envelope viruses and inactivated envelope viruses can be obtained by the steps consisting of:

[0123](1) mixing a protein containing (a) a polypeptide having an affinity for an envelope viral component and (b) a polypeptide having the ability to bind to the foreign substance to be incorporated into a cell, with said foreign substance to form a complex,

[0124](2) mixing the resulting mixture from the above step (1) with the envelope virus or inactivated envelope virus, and

[0125](3) subjecting the resulting mixture from the above step (2) to a treatment affecting the permeability of the envelope.

[0126]In the above methods 1 and 2, the treatment affecting the permeability of envelopes includes freeze-thawing, sonication, surface active agent addition and others. The addition of surface active agents is more preferable. The surface active agents used herein include octylglycoside, Triton-X 100, CHAPS, NP-40, etc. They can be used alone or in the form of combinations of two or more surface active agents. When the aforementioned surface active agent addition is applied for the treatment affecting the permeability of envelopes, the final concentration of surface active agents varies depending on kinds thereof but is 0.002 to 20%, desirably 0.02 to 2%. When the surface active agent is used, it is preferable to remove the surface active agent 1 min to 1 hr later. In the application of the above method 1, it is desirable to remove the surface active agent prior to the step (3) of admixing with the foreign substance. In the application of the above method 2, it is desirable to remove the surface active agent after the step (3). The removal of surface active agents includes methods of subjecting a mixture to centrifugation and discarding supernatants. The surface active agent treatment is preferably conducted at low temperature, more preferably under ice-cooling.

[0127]Use of envelope viruses and inactivated envelope viruses that contain foreign substances (non-self substances) within their envelopes, obtained by using the proteins of the present invention, allows the incorporation of said foreign substances into one or more cells. Said foreign substances can be incorporated into one or more cells by contacting the cell or cells to be targeted for the incorporation with the envelope viruses and inactivated envelope viruses that contain the foreign substance (non-self substance) within their envelopes.

[0128]Cells to be targeted for the incorporation of foreign substances in the present invention are any of cultured cells and cells which compose tissues. Preferred target cells are cultured cells. Embodiments of the cells are any cell of mammals (e.g., human, bovine, simian, equine, swine, ovine, caprine, canine, feline, guinea pig, rat, mouse, rabbit, hamster, etc.). Examples of such cells are hepatocytes, splenocytes, neurons, gliacytes, pancreatic β cells, myelocytes, mesangial cells, Langerhans' cells, epidermic cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fibrocytes, myocytes, fat cells (adipocytes), immune cells (e.g., macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells (osteocytes), osteoblasts, osteoclasts, mammary gland cells and interstitial cells (Leydig's cells), precursor cells of these cells, stem cells and cancer cells and other cells. The targets for the incorporation of said foreign substances may be any tissue wherein one or more members of such cells exist, including, for example, brain, any part thereof (e.g., olfactory bulb, amygdaloid nucleus, cerebral basal ganglia, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla oblongata, cerebellum), spinal cord, hypophysis, stomach, pancreas, kidney, liver, gonad, thyroid, gallbladder, bone marrow, adrenal gland, skin, lung, gastrointestinal tract (e.g., large intestine and small intestine), blood vessel, heart, thymus, spleen, submandibular gland, peripheral blood, prostate, testis, ovary, placenta, uterus, bone, joint, adipose tissue (e.g., brown adipose tissue, white adipose tissue), skeletal muscle and other tissues.

[0129]The present invention will be more specifically illustrated by the following Examples, but such examples are not intended to limit the scope of the present invention.

[0130]Details of the present invention are described by the following examples but such examples are provided only for illustrative purposes, and for referential embodiments of the present invention. These examples have been described herein for the purpose of illustrating specific embodiments of the present invention but should not be construed as in any sense limiting the scope of the invention disclosed herein. It should be understood in the present invention that various embodiments can be made or executed within the spirit, scope and concept disclosed herein. All the examples were carried out or can be carried out, unless otherwise disclosed herein specifically, by standard techniques which are well known and conventional to those skilled in the art.

EXAMPLE 1

Construction of Vector for Expressing Antibody-Binding ZZ Protein (Synthetic Peptide ZZ Region)

[0131]In order to utilize the antibody-binding Z region, a DNA fragment coding for the ZZ region, which is the tandem repeat dimer of said region, was inserted into the site downstream of the T7 promoter of inducible expression vector pET28a (Novagen). The above-described ZZ region DNA fragment was prepared by performing PCR using pEZZ18 (Amersham Biosciences) as a template.

[0132]Primers used in PCR were primer 1 (5'-GCAAATGCCATGGAACACGATGAAGCCGTAGACAA-3'; SEQ ID NO: 7) and primer 2 (5'-GGATCACCAAGCTTTTAGCTCGAATTCGCGTCTAC-3'; SEQ ID NO: 8), for generating NcoI and Hind III restriction sites at the upstream and downstream ends of the ZZ region in the resulting DNA fragment, respectively. The PCR was done using Ex Taq® (Takara), in 50 μl of reaction solution (a reaction buffer attached to Ex Taq®, 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of pEZZ18. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 94° C. for 30 sec, at 60° C. for 30 sec and at 72° C. for 30 sec, for a total of 30 cycles. The resultant DNA fragment was digested with restriction enzymes, NcoI and Hind III, and then inserted into the site derived by cleavage with NcoI and Hind III from pET28a (Novagen) to create inducible expression vector pETZZ.

EXAMPLE 2

Preparation of DNA Coding for HVJ Nucleocapsid Protein

[0133]DNA coding for HVJ nucleocapsid protein was RT-PCR amplified from genome RNA of HVJ Z strain (furnished by courtesy of Professor Kaneda, Osaka University, Japan). The aforementioned virus which can be used herein is HVJ virus in HVJ-inoculated chicken egg chorioallantoic fluid obtainable in the same manner as disclosed in Example 1 of US Patent Application Publication No. 2004/0253272 A1. Purification of total RNA was done with Viral RNA Mini (Viogene) from virus-infected chicken egg chorioallantoic fluid.

[0134]Reverse transcription was carried out with Ready-To-Go® You-Prime First-Strand Beads (Amersham Biosciences) using purified total RNA in combination with virus genome RNA-specific primers, primer 3 (5'-ACCAAACAAGAGAAAAAACATGTAT-3'; SEQ ID NO: 9). In the RT reaction step, 20 μl of RNase free water was added to 10 μl of total RNA solution (16 ng/μl) and the resultant mixture was allowed to stand at 65° C. for 10 min, and then put on ice for 2 min. The resulting mix was added to First-Strand Reaction Mix Beads, admixed with 3 μl of primer 3 (10 μM), and then allowed to stand at 37° C. for 1 hr to give a virus genome cDNA solution.

[0135]PCR was performed using as a template the resulting virus genome cDNA from the above reaction in combination with primers, primer 4 (5'-TGCCAAAGGATCCGATGGCCGGGTTGTTGAGCACC-3'; SEQ ID NO: 10) and primer 5 (5'-GCCTCGTCTCGAGCTAGATTCCTCCTACCCCAGCT-3'; SEQ ID NO: 11), for generating BamH I and Xho I restriction sites at the upstream and downstream ends of the DNA region coding for the nucleocapsid protein in the resulting DNA fragment, respectively. The PCR was done using Ex Taq® (Takara) in 49 μl of reaction solution (a reaction buffer attached to Ex Taq®, 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with 1 μl of the virus genome cDNA solution. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 94° C. for 30 sec, at 60° C. for 30 sec and at 72° C. for 2 min, for a total of 30 cycles. As a result, a DNA sample (1 μg) containing DNA coding for the nucleocapsid protein was obtained.

EXAMPLE 3

Preparation of Plasmid for Expressing Fusion Protein Composed of ZZ Protein and HVJ Nucleocapsid Protein

[0136]HVJ nucleocapsid protein-encoding DNA was inserted into the downstream site of the ZZ protein-encoding DNA sequence of pETZZ, obtained in the above Example 1, to create plasmid pETZZNP for expressing fusion proteins. The DNA fragment, obtained in the above Example 2, was cleaved with BamH I and Xho I, and then inserted into the site, derived by cleavage with BamH I and Xho I from pETZZ, to create plasmid pETZZNP for expressing a fusion protein (ZZ-NP) with HVJ nucleocapsid protein on the C-terminal end of ZZ protein.

EXAMPLE 4

Preparation of Fusion Protein Composed of Zz Protein and HVJ Nucleocapsid Protein

[0137]Fusion protein ZZ-NP was inducibly expressed in E. coli using T7 expression system. E. coli Rosetta (DE3) (Novagen) was transformed with pETZZNP, obtained in the above Example 3, and the resulting transformants (transformed cells) were incubated in LB culture medium (30 ml) containing kanamycin (final concentration: 20 μg/ml) and chloramphenicol (final concentration: 34 μg/ml) at 37° C. overnight. The resultant culture was used as a preculture solution. This preculture solution was transferred in 1 L of LB culture medium containing kanamycin (final concentration: 20 μg/ml) and chloramphenicol (final concentration: 34 μg/ml), and incubated. When the culture was grown to OD₆₀₀=0.6, expression was induced by adding 1 ml of 1M IPTG solution. After further incubation at 37° C. for 4 hr, the culture was centrifuged (at 4° C., 6,000 rpm for 15 min), and cells were collected and stored overnight at -20° C. The resultant cells were suspended in 20 ml of TST solution (50 mM Tris, pH7.6, 150 mM NaCl, 0.05% Tween 20) and then disrupted by sonication. The crude extract was centrifuged (at 4° C., 20,000 g for 30 min), and the resulting supernatant was subjected to affinity purification using IgG Sepharose® 6 Fast Flow (Amersham Biosciences) according to attached manuals. The column was equilibrated with 0.5M acetic acid (pH3.4), TST (50 mM Tris buffer, pH7.6, 150 mM NaCl, 0.05% Tween 20) and loaded with the above supernatant. The column was washed with TST, 5 mM NH₄Ac (pH5.0), and then eluted with 0.5M acetic acid (pH3.4). The fusion protein containing eluate (2 ml) was dialyzed against 300 mL of PBS for 2 hr, and further against 300 ml of PBS overnight, with dialysis membrane, Spectra/Por Membrane MWCO: 1,000 (Spectrum). After the dialysis, the resulting fusion protein solution (2 ml) was sterilized by filtration through a 0.22 μm filter. A fusion protein ZZ-NP solution (2 ml) with the fusion protein ZZ-NP concentration of 2 mg/mL was obtained.

EXAMPLE 5

Preparation of Fusion Protein Zz-NP-Containing Inactivated HVJ Envelope

[0138]To 20 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) solution was added 20 μl of fusion protein ZZ-NP solution (adjusted to 2 mg/ml), obtained in the above Example 4, and the resultant solution was mixed. To the mixture was added 4 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min). After the centrifugation, supernatants were removed, PBS was gently added at a dose of 20 μl, and the mixture was recentrifuged (at 4° C., 10,000 g, for 5 min). After the centrifugation, supernatants were removed, and free ZZ-NP was removed. To the resultant pellets was added 10 μl of PBS to form a suspension. To the above suspension was also added 10 μl of 2× sample buffer and the mixture was boiled for 5 min. The resulting mixture was applied to SDS-PAGE (10% acrylamide gel), and CBB staining was done after the electrophoresis (FIG. 1, Lane 2). For control groups, inactivated HVJ envelope wherein the same operations were done except that no ZZ-NP is used (FIG. 1, lane 1) and ZZ-NP alone (FIG. 1, lane 3) were electrophoresed.

[0139]On lane 1, no band corresponding to ZZ-NP is observed. In contrast, a band corresponding ZZ-NP is verified on lane 2, indicating that fusion protein ZZ-NP containing inactivated HVJ envelopes have been obtained by the above treatment.

EXAMPLE 6

Preparation of Mouse Igg-Containing Inactivated HVJ Envelope

[0140]To 10 μl of a 25HAU/R1 inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of ZZ-NP solution (predetermined ZZ-NP concentration: 0.08 to 2 mg/ml) and the resultant solution was mixed. To the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resulting ZZ-NP-containing inactivated HVJ envelope was suspended in 10 μl of antibody solution (1 mg/ml Mouse IgG (SIGMA), PBS) and then allowed to stand on ice for 5 min. The suspension was centrifuged (at 4° C., 10,000 g, for 5 min) and supernatants were removed. To the resultant pellets was gently added 20 μl of PBS, the mixture was centrifuged (4° C., 10,000 g, 5 min), and supernatants were removed. To the resultant pellets was added 10 μl of PBS to form a suspension. To the above suspension was also added 10 μl of 2× sample buffer and the mixture was boiled for 5 min. The resulting mixture was applied to SDS-PAGE (10% acrylamide gel). After the electrophoresis, samples were electroblotted (60 min, 2 mA/cm²) onto a PVDF membrane (ATTO). After the blotting, blocking was done by dipping this PVDF membrane into TBS-T solution (0.1% Tween 20-containing TBS) containing 5% skim milk for 1 hr. Next, this blocked PVDF membrane was washed with TBS-T for 5 min, and then dipped into a TBS-T solution containing anti-mouse Ig antibody solution (Anti-Mouse Ig HRP-Linked Whole Ab, Amersham Biosciences) and 0.1% BSA for 1 hr. Thereafter, 5 min washing with TBS-T was repeated 3 times and mouse IgG was then detected with ECL PLUS western blotting detection reagents kit (Amersham Biosciences) (FIG. 2). It has been disclosed that mouse IgG is present in inactivated HVJ envelope pellets receiving the above treatment. ZZ-NP used increased the amounts of incorporated antibodies in a dose-dependent manner (lane 4: 0.8 μg, lane 5: 4 μg, lane 6: 20 μg).

EXAMPLE 7

Preparation of Anti-NPC (Nuclear Pore Complex) Antibody-Containing Inactivated HVJ Envelope

[0141]To 10 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of 2 mg/ml ZZ-NP solution and the resultant solution was mixed. To the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resultant pellets were suspended in 10 μl of 1 mg/ml Anti-NPC antibody (SIGMA) solution. After standing on ice for 5 min, the mixture was centrifuged (4° C., 10,000 g, 5 min) and supernatants were removed. To the resulting Anti-NPC (Nuclear Pore Complex) antibody-containing inactivated HVJ envelope was added 11.25 μl of PBS, and next 1.25 μl of 10 mg/ml protamine sulfate solution, to form a suspension.

EXAMPLE 8

Inactivated HVJ Envelope-Mediated Introduction of Anti-NPC Antibodies into Cultured Cells

[0142]HeLa S3 cells (furnished by courtesy of Professor Kaneda, Osaka University, Japan) were seeded at 1×10 cells/0.7 cm², and incubated in a carbon dioxide gas incubator overnight. To the resulting cultured cells was added 5 μl of Anti-NPC antibody-containing inactivated HVJ envelope suspension, obtained in the above Example 7, and the cells were placed in a carbon dioxide gas incubator. Four hours later, the cells were washed twice with PBS, and fixed by treatment with a PBS solution containing 4% paraformaldehyde for 15 min. Next, the cells were washed twice with PBS, and then perfused in a PBS solution containing 0.2% Triton X-100 for 5 min. After the treatment, the cells were washed twice with PBS for 5 min, and then treated with a PBS solution containing 1% BSA for 10 min. Next, the cells were allowed to stand in a PBS solution containing 1% BSA and 4 μg/ml Alexa Fluor 488-labeled Goat Anti-Mouse IgG, F(ab')₂ fragment (Invitrogen) for 1 hr. After washing 3 times with PBS for 5 min at the final step, the cells were observed using confocal laser microscope FV300 (OLYMPUS, Japan) equipped with an Argon laser (FIG. 3). In cytoplasms transfected with Anti-NPC antibody-containing inactivated HVJ envelopes, nuclear membranes were discriminated with labeled secondary antibodies [FIG. 3(1)]. It has been disclosed that Anti-NPC antibodies incorporated into cells retain the property of recognizing nucleic membranes.

EXAMPLE 9

Preparation of Plasmid for Expressing Fusion Protein Composed of ZZ Protein and Partly Deficient Nucleocapsid Protein

[0143]Nucleocapsid-encoding DNA of pETZZNP, obtained in the above Example 3, was partly deleted to construct pET-ZZK1 to 4.

(1) Construction of pET-ZZK1, pET-ZZK2 and pET-ZZK3

[0144]PCR was performed using as a template pET-ZZNP and each primer set, primer 6 (5'-TAGCTCGAGCACCACCAC-3'; SEQ ID NO: 20) in combination with primer 7 (5'-GTTTGCCAGATGATGTCT-3'; SEQ ID NO: 21); primer 6 (5'-TAGCTCGAGCACCACCAC-3'; SEQ ID NO: 20) in combination with primer 8 (5'-AAGGTATGTCCTCCCTGT-3'; SEQ ID NO: 22); and primer 6 (5'-TAGCTCGAGCACCACCAC-3'; SEQ ID NO: 20) in combination with primer 9 (5'-AACTATCTGGATGTTCTT-3'; SEQ ID NO: 23), respectively. The PCR was done using Pyrobest DNA Polymerase (Takara), in 50 μl of reaction solution (a reaction buffer attached to Pyrobest® DNA Polymerase, 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of pETZZNP. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 98° C. for 10 sec, at 60° C. for 30 sec and at 72° C. for 7 min, for a total of 30 cycles. The resultant DNA fragments were subjected to self-ligation to form pET-ZZK1, pET-ZZK2 and pET-ZZK3.

(2) Construction of pET-ZZK4

[0145]PCR was performed using as a template pET-ZZK1 in combination with primers, primer 10 (5'-CGGATCCCCGGGTACCGAGCTCGAATT-3'; SEQ ID NO: 24) and primer 11 (5'-GGGAACTACATCCGAGATGCAG-3'; SEQ ID NO: 25) in the same fashion as in the above (1) to create pET-ZZK4.

EXAMPLE 10

Preparation of Fusion Proteins (ZZ-NPK1, ZZ-NPK2, ZZ-NPK3 and ZZ-NPK4) Composed of ZZ Protein and Partly Deficient Nucleocapsid Protein

[0146]Fusion proteins ZZ-NPK1, ZZ-NPK2, ZZ-NPK3, and ZZ-NPK4 were inducibly expressed in E. coli using T7 expression system. Specifically, E. coli Rosetta (DE3) (Novagen) was transformed with pET-ZZK1, pET-ZZK2, pET-ZZK3, and pET-ZZK4, respectively, obtained in the above Example 9, and the resulting transformants (transformed cells) were incubated in LB culture medium (30 ml) containing kanamycin (final concentration: 20 μg/ml) and chloramphenicol (final concentration: 34 μg/ml) at 37° C. overnight. Each of the resultant cultures was used as a preculture solution. This preculture solution was transferred in 1 L of LB culture medium containing kanamycin (final concentration: 20 μg/ml) and chloramphenicol (final concentration: 34 μg/ml), and incubated. When the culture was grown to OD₆₀₀=0.6, expression was induced by adding 1 ml of 1M IPTG solution. After further incubation at 37° C. for 4 hr, the culture was centrifuged (at 4° C., 6,000 rpm for 15 min), and cells were collected and stored overnight at -20° C. The resultant cells were suspended in 20 ml of TST solution (50 mM Tris, pH7.6, 150 mM NaCl, 0.05% Tween 20) and then disrupted by sonication. The crude extract was centrifuged (at 4° C., 20,000 g for 30 min), and the resulting supernatant was subjected to affinity purification using IgG Sepharose 6 Fast Flow (Amersham Biosciences) according to attached manuals. Briefly, the column was equilibrated with 0.5M acetic acid (pH3.4), TST (50 mM Tris buffer, pH7.6, 150 mM NaCl, 0.05% Tween 20) and loaded with the above supernatant. The column was washed with TST, 5 mM NH₄Ac (pH5.0), and then eluted with 0.5M acetic acid (pH3.4) to obtain target products. The fusion protein containing eluate (2 ml) was dialyzed against 300 mL of PBS for 2 hr, and further against 300 ml of PBS overnight, with dialysis membrane, Spectra/Por Membrane MWCO: 1,000 (Spectrum). After the dialysis, the resulting fusion protein solution (2 ml) was sterilized by filtration through a 0.22 μm filter to give target fusion protein, ZZ-NPK1, ZZ-NPK2, ZZ-NPK3, or ZZ-NPK4. For each sequence of partly deleted nucleocapsid protein products, obtained in this experiment, NPK1 is shown in SEQ ID NO: 26 and 27, NPK2 in SEQ ID NO: 28 and 29, NPK3 in SEQ ID NO: 30 and 31, NPK4 in SEQ ID NO: 32 and 33, respectively.

EXAMPLE 11

Fusion Protein (ZZ-NPK1, ZZ-NPK2, ZZ-NPK3, ZZ-NPK4 or ZZ-NP)-Mediated Preparation of Mouse IgG-Containing Inactivated HVJ Envelope

[0147]To 10 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of ZZ-NPK1, ZZ-NPK2, ZZ-NPK3, ZZ-NPK4 (all obtained in Example 10) or ZZ-NP (obtained in Example 4) solution (adjusted to 1 mg/ml) and the resultant solution was mixed. Next, to the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resulting respective ZZ fusion protein-containing inactivated HVJ envelope was suspended in 10 μl of antibody solution (1 mg/ml Mouse IgG (SIGMA), PBS) and then allowed to stand on ice for 5 min. The suspension was centrifuged (at 4° C., 10,000 g, for 5 min) and supernatants were removed. To the resultant pellets was gently added 10 μl of PBS, the mixture was recentrifuged (4° C., 10,000 g, 5 min), and supernatants were removed. To the resultant pellets was added 10 μl of PBS to form a suspension. To the above suspension was also added 10 μl of 2× sample buffer and the mixture was boiled for 5 min. The resulting mixture was applied to SDS-PAGE (10% acrylamide gel). After the electrophoresis, samples were electroblotted (60 min, 2 mA/cm²) onto a PVDF membrane (ATTO). After the blotting, blocking was done by dipping this PVDF membrane into TBS-T solution (0.1% Tween 20-containing TBS) containing 5% skim milk for 1 hr. Next, this blocked PVDF membrane was washed with TBS-T for 5 min, and then dipped into a TBS-T solution containing Peroxidase-conjugated AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG (H+L) (Jackson Immuno Research Laboratories) and 0.1% BSA for 1 hr. Thereafter, 5 min washing with a TBS-T solution was repeated 3 times and mouse IgG was then detected with ECL PLUS western blotting detection reagents kit (Amersham Biosciences) (FIG. 4). It has been disclosed that mouse IgG is present in inactivated HVJ envelope pellets receiving the above treatments with fusion proteins. Among fusion proteins used, the highest incorporation level of mouse IgG into the inactivated HVJ envelope was observed when ZZ-NPK1 was used.

EXAMPLE 12

Preparation of Anti-NPC (Nuclear Pore Complex) Antibody-Containing Inactivated HVJ Envelope

[0148]To 5 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 5 μl of 0.5 mg/ml ZZ-NPK1 solution and the resultant solution was mixed. To the mixture was added 1 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resultant pellets were suspended in 5 μl of 0.25 mg/ml Anti-NPC antibody (SIGMA) solution. After standing on ice for 5 min, the mixture was centrifuged (4° C., 10,000 g, 5 min) and supernatants were removed. To the resulting Anti-NPC (Nuclear Pore Complex) antibody (Ab)-containing inactivated HVJ envelope was added 6.25 μl of PBS, and next 6.25 μl of 1 mg/ml protamine sulfate solution, to form a suspension.

EXAMPLE 13

Inactivated HVJ Envelope-Mediated Introduction of Anti-NPC Ab into Cultured Cells

[0149]HeLa S3 cells (furnished by courtesy of Professor Kaneda, Osaka University, Japan) were seeded at 1×10⁴ cells/0.7 cm², and incubated in a carbon dioxide gas incubator overnight. To the resulting cultured cells was added 10 μl of Anti-NPC Ab-containing inactivated HVJ envelope suspension, obtained in the above Example 12, and the mixture was placed in a carbon dioxide gas incubator. Four hours later, the cells were washed twice with PBS, and fixed by treatment with a PBS solution containing 4% paraformaldehyde for 15 min. Next, the cells were washed twice with PBS, and then perfused in a PBS solution containing 0.2% Triton X-100 for 5 min. After the treatment, the cells were washed twice with PBS for 5 min, and then treated with a PBS solution containing 1% BSA for 10 min. Next, the cells were allowed to stand in a PBS solution containing 1% BSA and 4 μg/ml Alexa Fluor 488-labeled Goat Anti-Mouse IgG, F(ab')₂ fragment (Invitrogen) for 1 hr. After washing 3 times with PBS for 5 min at the final step, the cells were analyzed using confocal laser microscope FV300 (OLYMPUS, Japan) equipped with an Argon laser. For controls, the same treatments were repeated using a solution containing Anti-NPC Ab alone in place of the above-described Anti-NPC Ab-containing inactivated HVJ envelope suspension.

[0150]While no incorporation of antibodies into cells was observed in case of Anti-NPC Ab alone, nuclear membranes were discriminated with labeled secondary antibodies in cells Anti-NPC Ab-transfected with ZZ-NPK1-containing inactivated HVJ envelopes (FIG. 5).

EXAMPLE 14

Construction of Plasmids for Expressing Fusion Proteins Composed of Protein G C1 Region or its Tandem Repeat Dimer Protein and partly deficient Nucleocapsid Protein (NPK1)

[0151]PCR was performed using as a template pET28a (Novagen) in combination with primers, primer 12 (5'-GAAGCGGTTGATGCTGCTACCGCAGAAAAAGTTTTCAAACAGTA CGCTAACAGCATGACTGGTGGACAG-3': SEQ ID NO: 34) and primer 13 (5'-AGTAGTGGTTTCGCCTTTCAAGGTTTTACCATTCAGGATTAATT TGTAGGTCATGGTATATCTCCTTCT-3': SEQ ID NO: 35). The PCR was done using Pyrobest DNA Polymerase (Takara), in 50 μl of reaction solution (a reaction buffer attached to Pyrobest DNA Polymerase, 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of template plasmid. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 98° C. for 10 sec, at 58° C. for 30 sec and at 72° C. for 6 min, for a total of 30 cycles. The resultant DNA fragment was subjected to self-ligation to form pETG1 coding for an half (N-terminal side) of the Protein G C1 region.

[0152]Further, PCR was performed using as a template pETG1, in combination with primers, primer 14 (5'-GTTACTGAAAAACCGGAAGTGATCGATGCGTCTGAATTAACCCC GGCGGTGACCCTGAGATCCGGCTGCTAA-3': SEQ ID NO: 36) and primer 15 (5'-GGTAAAGGTTTTAGTCGCATCGTCGTAGGTCCATTCACCGTCAA CACCGTTGTCGTTAGCGTACTGTTTGAA-3'; SEQ ID NO: 37). The PCR was done in the same fashion as above, followed by self-ligation, to obtain pETG2 coding for the full length Protein G C1 region.

[0153]Next, PCR was performed using as a template pETG2, in combination with primers, primer 16 (5'-ATGCGTCCGGCGTAGA-3'; SEQ ID NO: 38) and primer 17 (5'-TAGCAGTTGGAATTCGCGGTCACCGCCGGGGTTAA-3'; SEQ ID NO: 39). The PCR was done using Ex Taq (Takara), in 50 μl of reaction solution (a reaction buffer attached to Ex Taq (Takara), 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of template plasmid. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 94° C. for 30 sec, at 58° C. for 30 sec and at 72° C. for 1 min, for a total of 30 cycles. The resultant DNA fragment was digested with restriction enzymes, Xba I and EcoR I, and then inserted into the site derived by cleavage with Xba I and EcoR I from pET-ZZNPK1 to create plasmid pET-GNPK1 for expressing a fusion protein composed of Protein G C1 region and NPK1.

[0154]PCR was performed using as a template pETG2 in combination with primers, primer 18 (5'-AGGAGATAGAATTCTACCTACAAATTAATCCTGAA-3'; SEQ ID NO: 40) and primer 17 (5'-AAGGTATGTCCTCCCTGT-3'; SEQ ID NO: 39). The PCR was done in the same fashion as above. The resultant DNA fragment was digested with restriction enzyme, EcoR I, and then inserted into the site derived by cleavage with EcoR I from pET-GNPK1 to create plasmid pET-GGNPK1 for expressing a fusion protein composed of the tandem repeat dimer of Protein G C1 region and NPK1.

EXAMPLE 15

Construction of Plasmids for Expressing Fusion Proteins Composed of Protein L B1 Region or its Tandem Repeat Dimer Protein and partly deficient Nucleocapsid Protein (NPK1)

[0155]PCR was performed using as a template pET28a (Novagen) in combination with primers, primer 19 (5'-AACCTGATCTTTGCGAACGGCAGCACCCAGACCGCGGAATTTAAA GGCACCTTTGAAAAAAGCATGACTGGTGGACAG-3'; SEQ ID NO: 41) and primer 20 (5'-CGCTTTGATGGTCACTTCTTCTTCGCTATCGGTTTCCGGGGTTTC CGGGGTTTCTTCTTTCATGGTATATCTCCTTCT-3'; SEQ ID NO: 42). The PCR was done using Pyrobest DNA Polymerase (Takara), in 50 μl of reaction solution (a reaction buffer attached to Pyrobest DNA Polymerase, 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of template plasmid. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 98° C. for 10 sec, at 58° C. for 30 sec and at 72° C. for 6 min, for a total of 30 cycles. The resultant DNA fragment was subjected to self-ligation to form pETL1 coding for an half (N-terminal side) of the Protein L B1 region.

[0156]Next, PCR was performed using as a template pETL1 in combination with primers, primer 21 (5'-TGAATATACCGTGGATGTGGCGGATAAAGGTTATACCCTGAA CATTAAATTTGCGGGTTTTTTGCTGAAAGGA-3'; SEQ ID NO: 43) and primer 22 (5'-CCGTTATCTTTTTTCAGGGTATCCGCATACGCATACGCTTCGC TGGTCGCTTTTTCAAAGGTACCTTTAA-3'; SEQ ID NO: 44). The PCR was done in the same fashion as above, followed by self-ligation, to obtain pETL2 coding for the full length Protein L B1 region.

[0157]Further, PCR was performed using as a template pETL2, in combination with primers, primer 23 (5'-ATGCGTCCGGCGTAGA-3'; SEQ ID NO: 45) and primer 24 (5'-TCCCCTGTCGAATTCGCACCCGCAAATTTAATGT-3'; SEQ ID NO: 46). The PCR was done using Ex Taq (Takara), in 50 μl of reaction solution (a reaction buffer attached to Ex Taq (Takara), 200 μM each of dATP, dTTP, dCTP and dGTP, and 400 nM each of said primers) admixed with about 1 ng of template plasmid. The amplification was performed using GeneAmp PCR system 9700 (PE Applied Biosystems) set to repeat steps at 94° C. for 30 sec, at 58° C. for 30 sec and at 72° C. for 1 min, for a total of 30 cycles. The resultant DNA fragment was digested with restriction enzymes, Xba I and EcoR I, and then inserted into the site derived by cleavage with Xba I and EcoR I from pET-ZZNPK1 to create plasmid pET-LNPK1 for expressing a fusion protein composed of Protein L B1 region and NPK1.

[0158]PCR was also performed using as a template pETL2 in combination with primers, primer 25 (5'-AGGAGATAGAATTCTAAAGAAGAAACCCCGGAAAC-3'; SEQ ID NO: 47) and primer 24 (5'-AAGGTATGTCCTCCCTGT-3'; SEQ ID NO: 46). The PCR was done in the same fashion as above. The resultant DNA fragment was digested with restriction enzyme, EcoR I, and then inserted into the site derived by cleavage with EcoR I from pET-LNPK1 to create plasmid pET-LLNPK1 for expressing a fusion protein composed of the tandem repeat dimer of Protein L B1 region and NPK1.

EXAMPLE 16

Preparation of Fusion Proteins G-NPK1, GG-NPK1, L-NPK1 and LL-NPK1 Composed of Protein G C1 Region, or Protein L B1 Region, and partly deficient Nucleocapsid Protein

[0159]Fusion proteins G-NPK1, GG-NPK1, L-NPK1 and LL-NPK1 were inducibly expressed in E. coli expression systems utilizing T7 RNA polymerase. E. coli Rosetta (DE3) (Novagen) was transformed with pET-GNPK1 and pET-GGNPK1, obtained in the above Example 14, and pET-LNPK1 and pET-LLNPK1, obtained in the above Example 15, and treated in the same fashion as in Example 10 to give target fusion proteins G-NPK1, GG-NPK1, L-NPK1 and LL-NPK1, respectively, provided that, for eluents upon the affinity purification of G-NPK1 and GG-NPK1, 0.1M glycine-HCl (pH2.7) was used in place of 0.5M acetic acid (pH3.4).

EXAMPLE 17

Fusion Protein G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1-Mediated Preparation of Rat IgG2b-Containing Inactivated HVJ Envelope

[0160]To 10 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1 (all obtained in Example 16) solution (adjusted to 1/2 mg/ml) and the resultant solution was mixed. Next, to the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resulting G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1-containing inactivated HVJ envelopes were suspended in 5 μl of antibody solution (1 mg/ml Rat IgG2b (R&D systems)) and then allowed to stand on ice for 5 min. The suspension was centrifuged (at 4° C., 10,000 g, for 5 min) and supernatants were removed. To the resultant pellets was gently added 20 μl of PBS, the mixture was recentrifuged (4° C., 10,000 g, 5 min), and supernatants were removed. To the resultant pellets was added 10 μl of PBS to form a suspension. To the above suspension was also added 10 μl of 2× sample buffer and the mixture was boiled for 5 min. The resulting mixture was applied to SDS-PAGE (10% acrylamide gel), and CBB staining was done after the electrophoresis (FIGS. 6 and 7). It has been disclosed that rat IgG2b is present in inactivated HVJ envelope pellets receiving the above treatment.

EXAMPLE 18

Preparation of Rat IgG2b-Containing Inactivated HVJ Envelope

[0161]To 10 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1 (all obtained in Example 16) solution (adjusted to 1/2 mg/ml) and the resultant solution was mixed. To the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resultant G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1-containing inactivated HVJ envelopes were suspended in 5 μl of antibody solution (rat IgG2b (R&D systems), 1 mg/ml) After standing on ice for 5 min, the mixture was centrifuged (4° C., 10,000 g, 5 min) and supernatants were removed. To the resulting rat IgG2b-containing inactivated HVJ envelopes was added 12.5 μl of PBS, and further 12.5 μl of 1 mg/ml protamine sulfate solution to form a suspension.

EXAMPLE 19

Inactivated HVJ Envelope-Mediated Introduction of Rat IgG2b into Cultured Cells

[0162]HeLa S3 cells (furnished by courtesy of Professor Kaneda, Osaka University, Japan) were seeded at 1×10⁴ cells/0.7 cm², and incubated in a carbon dioxide gas incubator (5% CO₂, 37° C.) overnight. To the resulting cultured cells was added 10 μl of rat IgG2b-containing inactivated HVJ envelope suspension, obtained in the above Example 18, and the mixture was placed in a carbon dioxide gas incubator. Four hours later, the cells were washed twice with PBS, and fixed by treatment with a PBS solution containing 4% paraformaldehyde for 15 min. Next, the cells were washed twice with PBS, and then perfused in a PBS solution containing 0.2% Triton X-100 for 5 min. After the treatment, the cells were washed twice with PBS for 5 min, and then treated with a PBS solution containing 1% BSA for 10 min. Next, the cells were allowed to stand in a PBS solution containing 1% BSA and 4 μg/ml Alexa Fluor 488-labeled chicken Anti-rat IgG (Invitrogen) for 1 hr at room temperature. After washing 3 times with PBS for 5 min at the final step, the cells were analyzed using confocal laser microscope FV300 (OLYMPUS, Japan) equipped with an Argon laser (FIG. 8). It has been verified that rat IgG2b antibodies are present homogeneously within cytoplasms transfected with rat IgG2b Ab-containing inactivated HVJ envelopes.

EXAMPLE 20

Fusion Protein G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1-Mediated Preparation of Anti-NPC (Nuclear Pore Complex) Antibody-Containing Inactivated HVJ Envelope

[0163]To 10 μl of a 25HAU/μl inactivated HVJ envelope (GenomONE®, Ishihara Sangyo Kaisha, Ltd., Japan) suspension was added 10 μl of G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1 (all obtained in Example 16) solution (adjusted to 1/2 mg/ml) and the resultant solution was mixed. Next, to the mixture was added 2 μl of 2% Triton X-100 solution, and centrifuged immediately (at 4° C., 10,000 g, for 5 min) to remove supernatants. The resulting G-NPK1, GG-NPK1, L-NPK1 or LL-NPK1-containing inactivated HVJ envelopes were suspended in 5 μl of antibody solution (Anti-NPC Ab, 1 mg/ml). After standing on ice for 5 min, the suspension was centrifuged (4° C., 10,000 g, 5 min) and supernatants were removed. To the resulting Anti-NPC Ab-containing inactivated HVJ envelopes was added 12.5 μl of PBS, and further 12.5 μl of 1 mg/ml protamine sulfate solution to form a suspension.

EXAMPLE 21

Inactivated HVJ Envelope-Mediated Introduction of Anti-NPC Antibodies into Cultured Cells

[0164]Tests for introducing Anti-NPC (Nuclear Pore Complex) Ab into cultured cells were conducted using Anti-NPC Ab-containing inactivated HVJ envelopes, obtained in Example 20, in the same manner as in Example 13. In cytoplasms transfected with Anti-NPC Ab-containing inactivated HVJ envelopes, nuclear membranes were discriminated with labeled secondary antibodies [FIG. 9(1) and (2)]. It has been disclosed that Anti-NPC antibodies incorporated into cells retain the property of recognizing nucleic membranes.

INDUSTRIAL APPLICABILITY

[0165]In accordance with the present invention, use of proteins containing a envelope viral component-compatible polypeptide, and envelope viruses or inactivated envelope viruses in combination with said proteins, enables proteins, antibodies, and other foreign substances (non-self substances) to be incorporated into one or more cells without damaging their properties, functions and structures, and such intracellular delivery techniques are time and quantity controllable and facilitate efficient introduction of foreign substances into cells. The present invention provides targeting techniques for a wide variety of cells including various adhesive and suspension cells and primarily cultured cells and applicable to animals (in vivo), as well as techniques which can adapt, combinations of molecules to be intracellularly introduced with targets thereof, toward diverse applications.

[0166]Thus, applications of the present invention facilitate in vivo and in vitro function analysis in unknown genes, in vivo and in vitro function analysis in targeted genes, all aspects of gene therapy including clinical studies and clinical trials, studies to evaluate the onset mechanisms of diseases and to prevent the disease onset, DDS (Drug Delivery System) studies and uses, function examinations of novel useful materials and new drug candidates and application studies thereof, and applications to Drug Discovery. In more specific embodiments, the present invention allows the development and research of antineoplastic actions, cytotoxic actions and control actions such as gene expression.

[0167]While the present invention has been described specifically in detail with reference to certain embodiments and examples thereof, it would be apparent that it is possible to practice it in other forms. In light of the disclosure, it will be understood that various modifications and variations are within the spirit and scope of the appended claims.

<Sequence Listing Free Text>

[0168]SEQ ID NO:3, Modified antigen binding amino acid sequence derived from B domain of Protein A (Staphylococcus aureus)SEQ ID NO:4, Modified antigen binding amino acid sequence derived from B domain of Protein A (Staphylococcus aureus)SEQ ID NO:5, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NP)SEQ ID NO:6, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NP)SEQ ID NO:7, Oligonucleotide to act as a primer for PCRSEQ ID NO:8, Oligonucleotide to act as a primer for PCRSEQ ID NO:9, Oligonucleotide to act as a primer for reverse transcriptionSEQ ID NO:10, Oligonucleotide to act as a primer for PCRSEQ ID NO: 11, Oligonucleotide to act as a primer for PCRSEQ ID NO:12, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK1)SEQ ID NO:13, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK1)SEQ ID NO:14, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK2)SEQ ID NO:15, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK2)SEQ ID NO:16, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK3)SEQ ID NO:17, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK3)SEQ ID NO:18, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK4)SEQ ID NO:19, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK4)SEQ ID NO:20, Oligonucleotide to act as a primer for PCRSEQ ID NO:21, oligonucleotide to act as a primer for PCRSEQ ID NO:22, Oligonucleotide to act as a primer for PCRSEQ ID NO:23, oligonucleotide to act as a primer for PCRSEQ ID NO:24, Oligonucleotide to act as a primer for PCRSEQ ID NO:25, Oligonucleotide to act as a primer for PCRSEQ ID NO:26, Sendai virus nucleocapsid protein (NPK1)SEQ ID NO:27, Sendai virus nucleocapsid protein (NPK1)SEQ ID NO:28, Sendai virus nucleocapsid protein (NPK2)SEQ ID NO:29, Sendai virus nucleocapsid protein (NPK2)SEQ ID NO:30, Sendai virus nucleocapsid protein (NPK3)SEQ ID NO:31, Sendai virus nucleocapsid protein (NPK3)SEQ ID NO:32, Sendai virus nucleocapsid protein (NPK4)SEQ ID NO:33, Sendai virus nucleocapsid protein (NPK4)SEQ ID NO:34, Oligonucleotide to act as a primer for PCRSEQ ID NO:35, Oligonucleotide to act as a primer for PCRSEQ ID NO:36, Oligonucleotide to act as a primer for PCRSEQ ID NO:37, Oligonucleotide to act as a primer for PCRSEQ ID NO:38, Oligonucleotide to act as a primer for PCRSEQ ID NO:39, Oligonucleotide to act as a primer for PCRSEQ ID NO:40, Oligonucleotide to act as a primer for PCRSEQ ID NO:41, Oligonucleotide to act as a primer for PCRSEQ ID NO:42, Oligonucleotide to act as a primer for PCRSEQ ID NO:43, Oligonucleotide to act as a primer for PCRSEQ ID NO:44, Oligonucleotide to act as a primer for PCRSEQ ID NO:45, Oligonucleotide to act as a primer for PCRSEQ ID NO:46, Oligonucleotide to act as a primer for PCRSEQ ID NO:47, Oligonucleotide to act as a primer for PCRSEQ ID NO:48, Antigen binding amino acid sequence derived from C1 domain of Protein G (Streptococcus G148)SEQ ID NO:49, Antigen binding amino acid sequence derived from C1 domain of Protein G (Streptococcus G148)SEQ ID NO:50, Antigen binding amino acid sequence derived from B1 domain of Protein L (Peptostreptococcus magnus)SEQ ID NO:51, Antigen binding amino acid sequence derived from B1 domain of Protein L (Peptostreptococcus magnus)SEQ ID NO:52, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (G-NPK1)SEQ ID NO:53, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (G-NPK1)SEQ ID NO:54, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (GG-NPK1)SEQ ID NO:55, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (GG-NPK1)SEQ ID NO:56, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (L-NPK1)SEQ ID NO:57, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (L-NPK1)SEQ ID NO:58, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (LL-NPK1)SEQ ID NO:59, Fusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (LL-NPK1)

Sequence CWU 1

5911575DNASendai virusCDS(1)..(1575) 1atg gcc ggg ttg ttg agc acc ttc gat aca ttt agc tct agg agg agc 48Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15gaa agt att aat aag tcg gga gga ggt gct gtt atc ccc ggc cag agg 96Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30agc aca gtc tca gtg ttc gta cta ggc cca agt gtg act gat gat gca 144Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45gac aag tta ttc att gca act acc ttc cta gct cac tca ttg gac aca 192Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60gat aag cag cac tct cag aga gga ggg ttc ctc gtc tct ctg ctt gcc 240Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80atg gct tac agt agt cca gaa ttg tac ttg aca aca aac gga gta aac 288Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95gcc gat gtc aaa tat gtg atc tac aac ata gag aaa gac cct aag agg 336Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110acg aag aca gac gga ttc att gtg aag acg aga gat atg gaa tat gag 384Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125agg acc aca gaa tgg ctg ttt gga cct atg gtc aac aag agc cca ctc 432Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140ttc cag ggt caa cgg gat gct gca gac cct gac aca ctc ctt caa atc 480Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160tat ggg tat cct gca tgc cta gga gca ata att gtc caa gtc tgg att 528Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175gtg ctg gtg aag gcc atc aca agc agc gcc ggc tta agg aaa ggg ttc 576Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190ttc aac agg tta gag gcg ttc aga caa gac ggc acc gtg aaa ggt gcc 624Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205tta gtt ttc act ggg gag aca gtt gag ggg ata ggc tcg gtt atg aga 672Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220tct cag caa agc ctt gta tct ctc atg gtt gag acc ctt gtg act atg 720Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240aat act gca aga tct gat ctc acc aca tta gag aag aac atc cag atc 768Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255gtt ggg aac tac atc cga gat gca ggg ctg gct tcc ttc atg aac act 816Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270att aaa tat ggg gtg gag aca aag atg gca gct cta acg ttg tca aac 864Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285ctg agg ccc gat att aat aag ctt aga agc ctc ata gac acc tac ctg 912Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300tca aaa ggc ccc aga gct ccc ttt atc tgt atc ctc aag gac cct gtt 960Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320cat ggt gaa ttt gct cca ggc aat tat cct gca cta tgg agt tac gcc 1008His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335atg gga gtc gcc gtc gta cag aac aag gca atg cag cag tac gtc aca 1056Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350ggg agg aca tac ctt gat atg gaa atg ttc tta cta gga caa gcc gtg 1104Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val355 360 365gca aag gat gct gaa tcg aag atc agc agt gcc ttg gaa gat gag tta 1152Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu370 375 380gga gtg acg gat aca gcc aag ggg agg ctc aga cat cat ctg gca aac 1200Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn385 390 395 400ttg tcc ggt ggg gat ggt gct tac cac aaa cca aca ggc ggt ggt gca 1248Leu Ser Gly Gly Asp Gly Ala Tyr His Lys Pro Thr Gly Gly Gly Ala405 410 415att gag gta gct cta gac aat gcc gat atc gac cta gaa aca aaa gct 1296Ile Glu Val Ala Leu Asp Asn Ala Asp Ile Asp Leu Glu Thr Lys Ala420 425 430cat gcg gac cag gac gct agg ggt tgg ggt gga gat agt ggt gaa aga 1344His Ala Asp Gln Asp Ala Arg Gly Trp Gly Gly Asp Ser Gly Glu Arg435 440 445tgg gca cgt cag gtg agt ggt ggc cac ttt gtc aca cta cat ggg gct 1392Trp Ala Arg Gln Val Ser Gly Gly His Phe Val Thr Leu His Gly Ala450 455 460gaa cgg tta gag gag gaa acc aat gat gag gat gta tca gac ata gag 1440Glu Arg Leu Glu Glu Glu Thr Asn Asp Glu Asp Val Ser Asp Ile Glu465 470 475 480aga aga ata gcc atg aga ctc gca gag aga cgg caa gag gat tct gca 1488Arg Arg Ile Ala Met Arg Leu Ala Glu Arg Arg Gln Glu Asp Ser Ala485 490 495acc cat gga gat gaa ggc cgc aat aac ggt gtc gat cac gac gaa gat 1536Thr His Gly Asp Glu Gly Arg Asn Asn Gly Val Asp His Asp Glu Asp500 505 510gac gat gcc gca gca gta gct ggg gta gga gga atc tag 1575Asp Asp Ala Ala Ala Val Ala Gly Val Gly Gly Ile515 5202524PRTSendai virus 2Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val355 360 365Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu370 375 380Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn385 390 395 400Leu Ser Gly Gly Asp Gly Ala Tyr His Lys Pro Thr Gly Gly Gly Ala405 410 415Ile Glu Val Ala Leu Asp Asn Ala Asp Ile Asp Leu Glu Thr Lys Ala420 425 430His Ala Asp Gln Asp Ala Arg Gly Trp Gly Gly Asp Ser Gly Glu Arg435 440 445Trp Ala Arg Gln Val Ser Gly Gly His Phe Val Thr Leu His Gly Ala450 455 460Glu Arg Leu Glu Glu Glu Thr Asn Asp Glu Asp Val Ser Asp Ile Glu465 470 475 480Arg Arg Ile Ala Met Arg Leu Ala Glu Arg Arg Gln Glu Asp Ser Ala485 490 495Thr His Gly Asp Glu Gly Arg Asn Asn Gly Val Asp His Asp Glu Asp500 505 510Asp Asp Ala Ala Ala Val Ala Gly Val Gly Gly Ile515 5203174DNAArtificialModified antigen binding amino acid sequence derived from B domain of Protein A (Staphylococcus aureus) 3gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 48Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile1 5 10 15tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 96Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln20 25 30agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 144Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala35 40 45aaa aag cta aat gat gct cag gcg ccg aaa 174Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55458PRTArtificialModified antigen binding amino acid sequence derived from B domain of Protein A (Staphylococcus aureus) 4Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile1 5 10 15Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln20 25 30Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala35 40 45Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 5551977DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein 5atg gaa cac gat gaa gcc gta gac aac aaa ttc aac aaa gaa caa caa 48Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa 96Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct 144Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45aac ctt tta gca gaa gct aaa aag cta aat gat gct cag gcg ccg aaa 192Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 240Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 288Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 336Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110aaa aag cta aat gat gct cag gcg ccg aaa gta gac gcg aat tcg agc 384Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat aca 432Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt gct 480Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc cca 528Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc cta 576Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg ttc 624Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205ctc gtc tct ctg ctt gcc atg gct tac agt agt cca gaa ttg tac ttg 672Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac ata 720Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag acg 768Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct atg 816Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac cct 864Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca ata 912Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc gcc 960Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa gac 1008Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag ggg 1056Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg gtt 1104Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca tta 1152Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380gag aag aac atc cag atc gtt ggg aac tac atc cga gat gca ggg ctg 1200Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400gct tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg gca 1248Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415gct cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga agc 1296Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430ctc ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc tgt 1344Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445atc ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat cct 1392Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460gca cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag gca 1440Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480atg cag cag tac gtc aca ggg agg aca tac ctt gat atg gaa atg ttc 1488Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe485 490 495tta cta gga caa gcc gtg gca aag gat gct gaa tcg aag atc agc agt 1536Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser500 505 510gcc ttg gaa gat gag tta gga gtg acg gat aca gcc aag ggg agg ctc 1584Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu515 520 525aga cat cat ctg gca aac ttg tcc ggt ggg gat ggt gct tac cac aaa 1632Arg His His Leu Ala Asn Leu Ser Gly Gly Asp Gly Ala Tyr His Lys530 535 540cca aca ggc ggt ggt gca att gag gta gct cta gac aat gcc gat atc 1680Pro Thr Gly Gly Gly Ala Ile Glu Val Ala Leu Asp Asn Ala Asp Ile545 550 555 560gac cta gaa aca aaa gct cat gcg gac cag gac gct agg ggt tgg ggt 1728Asp Leu Glu Thr Lys Ala His Ala Asp Gln Asp Ala Arg Gly Trp Gly565 570 575gga gat agt ggt gaa aga tgg gca cgt cag gtg agt ggt ggc cac ttt 1776Gly Asp Ser Gly Glu Arg Trp Ala Arg Gln Val Ser Gly Gly His Phe580 585 590gtc aca cta cat ggg gct gaa cgg tta gag gag gaa acc aat gat gag 1824Val Thr Leu His Gly Ala Glu Arg Leu Glu Glu Glu Thr Asn Asp Glu595 600 605gat gta tca gac ata gag aga aga ata gcc atg aga ctc gca gag aga 1872Asp Val Ser Asp Ile Glu Arg Arg Ile Ala Met Arg Leu Ala Glu Arg610 615 620cgg caa gag gat tct gca acc cat gga gat gaa ggc cgc aat aac ggt 1920Arg Gln Glu Asp Ser Ala Thr His Gly Asp Glu

Gly Arg Asn Asn Gly625 630 635 640gtc gat cac gac gaa gat gac gat gcc gca gca gta gct ggg gta gga 1968Val Asp His Asp Glu Asp Asp Asp Ala Ala Ala Val Ala Gly Val Gly645 650 655gga atc tag 1977Gly Ile6658PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein 6Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe485 490 495Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser500 505 510Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu515 520 525Arg His His Leu Ala Asn Leu Ser Gly Gly Asp Gly Ala Tyr His Lys530 535 540Pro Thr Gly Gly Gly Ala Ile Glu Val Ala Leu Asp Asn Ala Asp Ile545 550 555 560Asp Leu Glu Thr Lys Ala His Ala Asp Gln Asp Ala Arg Gly Trp Gly565 570 575Gly Asp Ser Gly Glu Arg Trp Ala Arg Gln Val Ser Gly Gly His Phe580 585 590Val Thr Leu His Gly Ala Glu Arg Leu Glu Glu Glu Thr Asn Asp Glu595 600 605Asp Val Ser Asp Ile Glu Arg Arg Ile Ala Met Arg Leu Ala Glu Arg610 615 620Arg Gln Glu Asp Ser Ala Thr His Gly Asp Glu Gly Arg Asn Asn Gly625 630 635 640Val Asp His Asp Glu Asp Asp Asp Ala Ala Ala Val Ala Gly Val Gly645 650 655Gly Ile735DNAArtificialOligonucleotide to act as a primer for PCR 7gcaaatgcca tggaacacga tgaagccgta gacaa 35835DNAArtificialOligonucleotide to act as a primer for PCR 8ggatcaccaa gcttttagct cgaattcgcg tctac 35925DNAArtificialOligonucleotide to act as a primer for reverse transcription 9accaaacaag agaaaaaaca tgtat 251035DNAArtificialOligonucleotide to act as a primer for PCR 10tgccaaagga tccgatggcc gggttgttga gcacc 351135DNAArtificialOligonucleotide to act as a primer for PCR 11gcctcgtctc gagctagatt cctcctaccc cagct 35121605DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK1) 12atg gaa cac gat gaa gcc gta gac aac aaa ttc aac aaa gaa caa caa 48Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa 96Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct 144Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45aac ctt tta gca gaa gct aaa aag cta aat gat gct cag gcg ccg aaa 192Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 240Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 288Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 336Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110aaa aag cta aat gat gct cag gcg ccg aaa gta gac gcg aat tcg agc 384Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat aca 432Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt gct 480Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc cca 528Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc cta 576Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg ttc 624Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205ctc gtc tct ctg ctt gcc atg gct tac agt agt cca gaa ttg tac ttg 672Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac ata 720Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag acg 768Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct atg 816Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac cct 864Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca ata 912Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc gcc 960Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa gac 1008Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag ggg 1056Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg gtt 1104Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca tta 1152Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380gag aag aac atc cag atc gtt ggg aac tac atc cga gat gca ggg ctg 1200Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400gct tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg gca 1248Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415gct cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga agc 1296Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430ctc ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc tgt 1344Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445atc ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat cct 1392Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460gca cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag gca 1440Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480atg cag cag tac gtc aca ggg agg aca tac ctt gat atg gaa atg ttc 1488Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe485 490 495tta cta gga caa gcc gtg gca aag gat gct gaa tcg aag atc agc agt 1536Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser500 505 510gcc ttg gaa gat gag tta gga gtg acg gat aca gcc aag ggg agg ctc 1584Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu515 520 525aga cat cat ctg gca aac tag 1605Arg His His Leu Ala Asn53013534PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK1) 13Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe485 490 495Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser500 505 510Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu515 520 525Arg His His Leu Ala Asn530141476DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK2) 14atg gaa cac gat gaa gcc gta gac aac aaa ttc aac aaa gaa caa caa 48Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa 96Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct 144Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45aac ctt tta gca gaa gct aaa aag cta aat gat gct cag gcg ccg aaa 192Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 240Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 288Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 336Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110aaa aag cta aat gat gct cag gcg ccg aaa gta gac gcg aat tcg agc 384Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat aca 432Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt gct 480Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc cca 528Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc cta 576Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg ttc 624Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205ctc gtc tct ctg ctt gcc atg gct tac agt agt

cca gaa ttg tac ttg 672Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac ata 720Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag acg 768Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct atg 816Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac cct 864Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca ata 912Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc gcc 960Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa gac 1008Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag ggg 1056Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg gtt 1104Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca tta 1152Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380gag aag aac atc cag atc gtt ggg aac tac atc cga gat gca ggg ctg 1200Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400gct tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg gca 1248Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415gct cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga agc 1296Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430ctc ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc tgt 1344Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445atc ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat cct 1392Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460gca cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag gca 1440Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480atg cag cag tac gtc aca ggg agg aca tac ctt tag 1476Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu485 49015491PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK2) 15Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu385 390 395 400Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala405 410 415Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser420 425 430Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys435 440 445Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro450 455 460Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala465 470 475 480Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu485 490161176DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK3) 16atg gaa cac gat gaa gcc gta gac aac aaa ttc aac aaa gaa caa caa 48Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa 96Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct 144Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45aac ctt tta gca gaa gct aaa aag cta aat gat gct cag gcg ccg aaa 192Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 240Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 288Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 336Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110aaa aag cta aat gat gct cag gcg ccg aaa gta gac gcg aat tcg agc 384Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat aca 432Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt gct 480Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc cca 528Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc cta 576Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg ttc 624Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205ctc gtc tct ctg ctt gcc atg gct tac agt agt cca gaa ttg tac ttg 672Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac ata 720Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag acg 768Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct atg 816Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac cct 864Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca ata 912Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc gcc 960Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa gac 1008Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag ggg 1056Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg gtt 1104Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca tta 1152Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380gag aag aac atc cag ata gtt tag 1176Glu Lys Asn Ile Gln Ile Val385 39017391PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK3) 17Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr130 135 140Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala145 150 155 160Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro165 170 175Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu180 185 190Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe195 200 205Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu210 215 220Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile225 230 235 240Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr245 250 255Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met260 265 270Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro275 280 285Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile290 295 300Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala305 310 315 320Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp325 330 335Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly340 345 350Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val355 360 365Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu370 375 380Glu Lys Asn Ile Gln Ile Val385 39018834DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK4) 18atg gaa cac gat gaa gcc gta gac aac aaa ttc aac aaa gaa caa caa 48Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa 96Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct 144Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45aac ctt tta gca gaa gct aaa aag cta aat gat gct cag gcg ccg aaa 192Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60gta gac aac aaa ttc aac aaa gaa caa caa aac gcg ttc tat gag atc 240Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80tta cat tta cct aac tta aac gaa gaa caa cga aac gcc ttc atc caa 288Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa gct 336Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110aaa aag cta aat gat gct cag gcg ccg aaa gta gac gcg aat tcg agc 384Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125tcg gta ccc ggg gat ccg ggg aac tac atc cga gat gca ggg ctg gct 432Ser Val Pro Gly Asp Pro Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala130 135 140tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg gca gct 480Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala145 150 155 160cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga agc ctc 528Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu165 170 175ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc tgt atc 576Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile180 185 190ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat cct gca 624Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala195 200 205cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag gca atg 672Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala Met210 215 220cag cag tac gtc aca ggg agg aca tac ctt gat atg gaa atg ttc tta 720Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu225 230 235 240cta gga caa gcc gtg gca aag gat gct gaa tcg aag atc agc agt gcc 768Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala245 250 255ttg gaa gat gag tta gga gtg acg gat aca gcc aag ggg agg ctc aga 816Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg260 265 270cat cat ctg gca aac tag 834His His Leu Ala Asn27519277PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (ZZ-NPK4) 19Met Glu His Asp Glu Ala Val Asp Asn Lys Phe Asn Lys Glu Gln Gln1 5 10 15Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln20 25 30Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala35 40 45Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys50 55 60Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile65 70 75 80Leu His Leu Pro Asn Leu Asn

Glu Glu Gln Arg Asn Ala Phe Ile Gln85 90 95Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala100 105 110Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Ala Asn Ser Ser115 120 125Ser Val Pro Gly Asp Pro Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala130 135 140Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala145 150 155 160Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu165 170 175Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile180 185 190Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala195 200 205Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala Met210 215 220Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu225 230 235 240Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala245 250 255Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg260 265 270His His Leu Ala Asn2752018DNAArtificialOligonucleotide to act as a primer for PCR 20tagctcgagc accaccac 182118DNAArtificialOligonucleotide to act as a primer for PCR 21gtttgccaga tgatgtct 182218DNAArtificialOligonucleotide to act as a primer for PCR 22aaggtatgtc ctccctgt 182318DNAArtificialOligonucleotide to act as a primer for PCR 23aactatctgg atgttctt 182427DNAArtificialOligonucleotide to act as a primer for PCR 24cggatccccg ggtaccgagc tcgaatt 272522DNAArtificialOligonucleotide to act as a primer for PCR 25gggaactaca tccgagatgc ag 22261203DNAArtificialSendai virus nucleocapsid protein (NPK1) 26atg gcc ggg ttg ttg agc acc ttc gat aca ttt agc tct agg agg agc 48Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15gaa agt att aat aag tcg gga gga ggt gct gtt atc ccc ggc cag agg 96Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30agc aca gtc tca gtg ttc gta cta ggc cca agt gtg act gat gat gca 144Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45gac aag tta ttc att gca act acc ttc cta gct cac tca ttg gac aca 192Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60gat aag cag cac tct cag aga gga ggg ttc ctc gtc tct ctg ctt gcc 240Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80atg gct tac agt agt cca gaa ttg tac ttg aca aca aac gga gta aac 288Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95gcc gat gtc aaa tat gtg atc tac aac ata gag aaa gac cct aag agg 336Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110acg aag aca gac gga ttc att gtg aag acg aga gat atg gaa tat gag 384Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125agg acc aca gaa tgg ctg ttt gga cct atg gtc aac aag agc cca ctc 432Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140ttc cag ggt caa cgg gat gct gca gac cct gac aca ctc ctt caa atc 480Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160tat ggg tat cct gca tgc cta gga gca ata att gtc caa gtc tgg att 528Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175gtg ctg gtg aag gcc atc aca agc agc gcc ggc tta agg aaa ggg ttc 576Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190ttc aac agg tta gag gcg ttc aga caa gac ggc acc gtg aaa ggt gcc 624Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205tta gtt ttc act ggg gag aca gtt gag ggg ata ggc tcg gtt atg aga 672Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220tct cag caa agc ctt gta tct ctc atg gtt gag acc ctt gtg act atg 720Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240aat act gca aga tct gat ctc acc aca tta gag aag aac atc cag atc 768Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255gtt ggg aac tac atc cga gat gca ggg ctg gct tcc ttc atg aac act 816Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270att aaa tat ggg gtg gag aca aag atg gca gct cta acg ttg tca aac 864Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285ctg agg ccc gat att aat aag ctt aga agc ctc ata gac acc tac ctg 912Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300tca aaa ggc ccc aga gct ccc ttt atc tgt atc ctc aag gac cct gtt 960Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320cat ggt gaa ttt gct cca ggc aat tat cct gca cta tgg agt tac gcc 1008His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335atg gga gtc gcc gtc gta cag aac aag gca atg cag cag tac gtc aca 1056Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350ggg agg aca tac ctt gat atg gaa atg ttc tta cta gga caa gcc gtg 1104Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val355 360 365gca aag gat gct gaa tcg aag atc agc agt gcc ttg gaa gat gag tta 1152Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu370 375 380gga gtg acg gat aca gcc aag ggg agg ctc aga cat cat ctg gca aac 1200Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn385 390 395 400tag 120327400PRTArtificialSendai virus nucleocapsid protein (NPK1) 27Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val355 360 365Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu370 375 380Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn385 390 395 400281074DNAArtificialSendai virus nucleocapsid protein (NPK2) 28atg gcc ggg ttg ttg agc acc ttc gat aca ttt agc tct agg agg agc 48Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15gaa agt att aat aag tcg gga gga ggt gct gtt atc ccc ggc cag agg 96Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30agc aca gtc tca gtg ttc gta cta ggc cca agt gtg act gat gat gca 144Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45gac aag tta ttc att gca act acc ttc cta gct cac tca ttg gac aca 192Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60gat aag cag cac tct cag aga gga ggg ttc ctc gtc tct ctg ctt gcc 240Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80atg gct tac agt agt cca gaa ttg tac ttg aca aca aac gga gta aac 288Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95gcc gat gtc aaa tat gtg atc tac aac ata gag aaa gac cct aag agg 336Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110acg aag aca gac gga ttc att gtg aag acg aga gat atg gaa tat gag 384Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125agg acc aca gaa tgg ctg ttt gga cct atg gtc aac aag agc cca ctc 432Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140ttc cag ggt caa cgg gat gct gca gac cct gac aca ctc ctt caa atc 480Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160tat ggg tat cct gca tgc cta gga gca ata att gtc caa gtc tgg att 528Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175gtg ctg gtg aag gcc atc aca agc agc gcc ggc tta agg aaa ggg ttc 576Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190ttc aac agg tta gag gcg ttc aga caa gac ggc acc gtg aaa ggt gcc 624Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205tta gtt ttc act ggg gag aca gtt gag ggg ata ggc tcg gtt atg aga 672Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220tct cag caa agc ctt gta tct ctc atg gtt gag acc ctt gtg act atg 720Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240aat act gca aga tct gat ctc acc aca tta gag aag aac atc cag atc 768Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255gtt ggg aac tac atc cga gat gca ggg ctg gct tcc ttc atg aac act 816Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270att aaa tat ggg gtg gag aca aag atg gca gct cta acg ttg tca aac 864Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285ctg agg ccc gat att aat aag ctt aga agc ctc ata gac acc tac ctg 912Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300tca aaa ggc ccc aga gct ccc ttt atc tgt atc ctc aag gac cct gtt 960Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320cat ggt gaa ttt gct cca ggc aat tat cct gca cta tgg agt tac gcc 1008His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335atg gga gtc gcc gtc gta cag aac aag gca atg cag cag tac gtc aca 1056Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350ggg agg aca tac ctt tag 1074Gly Arg Thr Tyr Leu35529357PRTArtificialSendai virus nucleocapsid protein (NPK2) 29Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr260 265 270Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn275 280 285Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu290 295 300Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val305 310 315 320His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala325 330 335Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr340 345 350Gly Arg Thr Tyr Leu35530774DNAArtificialSendai virus nucleocapsid protein (NPK3) 30atg gcc ggg ttg ttg agc acc ttc gat aca ttt agc tct agg agg agc 48Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15gaa agt att aat aag tcg gga gga ggt gct gtt atc ccc ggc cag agg 96Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30agc aca gtc tca gtg ttc gta cta ggc cca agt gtg act gat gat gca 144Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45gac aag tta ttc att gca act acc ttc cta gct cac tca ttg gac aca 192Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60gat aag cag cac tct cag aga gga ggg ttc ctc gtc tct ctg ctt gcc 240Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80atg gct tac agt agt cca gaa ttg tac ttg aca aca aac gga gta aac 288Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95gcc gat gtc aaa tat gtg atc tac aac ata gag aaa gac cct aag agg 336Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110acg aag aca gac gga ttc att gtg aag acg aga gat atg gaa tat gag 384Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125agg acc aca gaa tgg ctg ttt gga cct atg gtc aac aag agc cca ctc 432Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140ttc cag ggt caa cgg gat gct gca gac cct gac aca ctc ctt caa atc 480Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160tat ggg tat cct gca tgc

cta gga gca ata att gtc caa gtc tgg att 528Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175gtg ctg gtg aag gcc atc aca agc agc gcc ggc tta agg aaa ggg ttc 576Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190ttc aac agg tta gag gcg ttc aga caa gac ggc acc gtg aaa ggt gcc 624Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205tta gtt ttc act ggg gag aca gtt gag ggg ata ggc tcg gtt atg aga 672Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220tct cag caa agc ctt gta tct ctc atg gtt gag acc ctt gtg act atg 720Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240aat act gca aga tct gat ctc acc aca tta gag aag aac atc cag ata 768Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255gtt tag 774Val31257PRTArtificialSendai virus nucleocapsid protein (NPK3) 31Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser1 5 10 15Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln Arg20 25 30Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp Ala35 40 45Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp Thr50 55 60Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu Ala65 70 75 80Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn85 90 95Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg100 105 110Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr Glu115 120 125Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro Leu130 135 140Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile145 150 155 160Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp Ile165 170 175Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe180 185 190Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly Ala195 200 205Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met Arg210 215 220Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr Met225 230 235 240Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile245 250 255Val32432DNAArtificialSendai virus nucleocapsid protein (NPK4) 32ggg aac tac atc cga gat gca ggg ctg gct tcc ttc atg aac act att 48Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr Ile1 5 10 15aaa tat ggg gtg gag aca aag atg gca gct cta acg ttg tca aac ctg 96Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn Leu20 25 30agg ccc gat att aat aag ctt aga agc ctc ata gac acc tac ctg tca 144Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu Ser35 40 45aaa ggc ccc aga gct ccc ttt atc tgt atc ctc aag gac cct gtt cat 192Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val His50 55 60ggt gaa ttt gct cca ggc aat tat cct gca cta tgg agt tac gcc atg 240Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala Met65 70 75 80gga gtc gcc gtc gta cag aac aag gca atg cag cag tac gtc aca ggg 288Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr Gly85 90 95agg aca tac ctt gat atg gaa atg ttc tta cta gga caa gcc gtg gca 336Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val Ala100 105 110aag gat gct gaa tcg aag atc agc agt gcc ttg gaa gat gag tta gga 384Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu Gly115 120 125gtg acg gat aca gcc aag ggg agg ctc aga cat cat ctg gca aac tag 432Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn130 135 14033143PRTArtificialSendai virus nucleocapsid protein (NPK4) 33Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn Thr Ile1 5 10 15Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser Asn Leu20 25 30Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu Ser35 40 45Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro Val His50 55 60Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala Met65 70 75 80Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val Thr Gly85 90 95Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala Val Ala100 105 110Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu Gly115 120 125Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala Asn130 135 1403469DNAArtificialOligonucleotide to act as a primer for PCR 34gaagcggttg atgctgctac cgcagaaaaa gttttcaaac agtacgctaa cagcatgact 60ggtggacag 693569DNAArtificialOligonucleotide to act as a primer for PCR 35agtagtggtt tcgcctttca aggttttacc attcaggatt aatttgtagg tcatggtata 60tctccttct 693672DNAArtificialOligonucleotide to act as a primer for PCR 36gttactgaaa aaccggaagt gatcgatgcg tctgaattaa ccccggcggt gaccctgaga 60tccggctgct aa 723772DNAArtificialOligonucleotide to act as a primer for PCR 37ggtaaaggtt ttagtcgcat cgtcgtaggt ccattcaccg tcaacaccgt tgtcgttagc 60gtactgtttg aa 723816DNAArtificialOligonucleotide to act as a primer for PCR 38atgcgtccgg cgtaga 163935DNAArtificialOligonucleotide to act as a primer for PCR 39tagcagttgg aattcgcggt caccgccggg gttaa 354035DNAArtificialOligonucleotide to act as a primer for PCR 40aggagataga attctaccta caaattaatc ctgaa 354178DNAArtificialOligonucleotide to act as a primer for PCR 41aacctgatct ttgcgaacgg cagcacccag accgcggaat ttaaaggcac ctttgaaaaa 60agcatgactg gtggacag 784278DNAArtificialOligonucleotide to act as a primer for PCR 42cgctttgatg gtcacttctt cttcgctatc ggtttccggg gtttccgggg tttcttcttt 60catggtatat ctccttct 784373DNAArtificialOligonucleotide to act as a primer for PCR 43tgaatatacc gtggatgtgg cggataaagg ttataccctg aacattaaat ttgcgggttt 60tttgctgaaa gga 734470DNAArtificialOligonucleotide to act as a primer for PCR 44ccgttatctt ttttcagggt atccgcatac gcatacgctt cgctggtcgc tttttcaaag 60gtacctttaa 704516DNAArtificialOligonucleotide to act as a primer for PCR 45atgcgtccgg cgtaga 164634DNAArtificialOligonucleotide to act as a primer for PCR 46tcccctgtcg aattcgcacc cgcaaattta atgt 344735DNAArtificialOligonucleotide to act as a primer for PCR 47aggagataga attctaaaga agaaaccccg gaaac 3548210DNAArtificialAntigen binding amino acid sequence derived from C1 domain of Protein G (Streptococcus G148) 48acc tac aaa tta atc ctg aat ggt aaa acc ttg aaa ggc gaa acc act 48Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr1 5 10 15act gaa gcg gtt gat gct gct acc gca gaa aaa gtt ttc aaa cag tac 96Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr20 25 30gct aac gac aac ggt gtt gac ggt gaa tgg acc tac gac gat gcg act 144Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr35 40 45aaa acc ttt acc gtt act gaa aaa ccg gaa gtg atc gat gcg tct gaa 192Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser Glu50 55 60tta acc ccg gcg gtg acc 210Leu Thr Pro Ala Val Thr65 704970PRTArtificialAntigen binding amino acid sequence derived from C1 domain of Protein G (Streptococcus G148) 49Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr1 5 10 15Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr20 25 30Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr35 40 45Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser Glu50 55 60Leu Thr Pro Ala Val Thr65 7050228DNAArtificialAntigen binding amino acid sequence derived from B1 domain of Protein L (Peptostreptococcus magnus) 50aaa gaa gaa acc ccg gaa acc ccg gaa acc gat agc gaa gaa gaa gtg 48Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu Val1 5 10 15acc atc aaa gcg aac ctg atc ttt gcg aac ggc agc acc cag acc gcg 96Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr Ala20 25 30gaa ttt aaa ggt acc ttt gaa aaa gcg acc agc gaa gcg tat gcg tat 144Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala Tyr35 40 45gcg gat acc ctg aaa aaa gat aac ggt gaa tat acc gtg gat gtg gcg 192Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val Ala50 55 60gat aaa ggt tat acc ctg aac att aaa ttt gcg ggt 228Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly65 70 755176PRTArtificialAntigen binding amino acid sequence derived from B1 domain of Protein L (Peptostreptococcus magnus) 51Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu Val1 5 10 15Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr Ala20 25 30Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala Tyr35 40 45Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val Ala50 55 60Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly65 70 75521446DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (G-NPK1) 52atg acc tac aaa tta atc ctg aat ggt aaa acc ttg aaa ggc gaa acc 48Met Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr1 5 10 15act act gaa gcg gtt gat gct gct acc gca gaa aaa gtt ttc aaa cag 96Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln20 25 30tac gct aac gac aac ggt gtt gac ggt gaa tgg acc tac gac gat gcg 144Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala35 40 45act aaa acc ttt acc gtt act gaa aaa ccg gaa gtg atc gat gcg tct 192Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser50 55 60gaa tta acc ccg gcg gtg acc gcg aat tcg agc tcg gta ccc ggg gat 240Glu Leu Thr Pro Ala Val Thr Ala Asn Ser Ser Ser Val Pro Gly Asp65 70 75 80ccg atg gcc ggg ttg ttg agc acc ttc gat aca ttt agc tct agg agg 288Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg85 90 95agc gaa agt att aat aag tcg gga gga ggt gct gtt atc ccc ggc cag 336Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln100 105 110agg agc aca gtc tca gtg ttc gta cta ggc cca agt gtg act gat gat 384Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp115 120 125gca gac aag tta ttc att gca act acc ttc cta gct cac tca ttg gac 432Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu Ala His Ser Leu Asp130 135 140aca gat aag cag cac tct cag aga gga ggg ttc ctc gtc tct ctg ctt 480Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu145 150 155 160gcc atg gct tac agt agt cca gaa ttg tac ttg aca aca aac gga gta 528Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val165 170 175aac gcc gat gtc aaa tat gtg atc tac aac ata gag aaa gac cct aag 576Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys180 185 190agg acg aag aca gac gga ttc att gtg aag acg aga gat atg gaa tat 624Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr195 200 205gag agg acc aca gaa tgg ctg ttt gga cct atg gtc aac aag agc cca 672Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro210 215 220ctc ttc cag ggt caa cgg gat gct gca gac cct gac aca ctc ctt caa 720Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln225 230 235 240atc tat ggg tat cct gca tgc cta gga gca ata att gtc caa gtc tgg 768Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp245 250 255att gtg ctg gtg aag gcc atc aca agc agc gcc ggc tta agg aaa ggg 816Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly260 265 270ttc ttc aac agg tta gag gcg ttc aga caa gac ggc acc gtg aaa ggt 864Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly275 280 285gcc tta gtt ttc act ggg gag aca gtt gag ggg ata ggc tcg gtt atg 912Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met290 295 300aga tct cag caa agc ctt gta tct ctc atg gtt gag acc ctt gtg act 960Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr305 310 315 320atg aat act gca aga tct gat ctc acc aca tta gag aag aac atc cag 1008Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln325 330 335atc gtt ggg aac tac atc cga gat gca ggg ctg gct tcc ttc atg aac 1056Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn340 345 350act att aaa tat ggg gtg gag aca aag atg gca gct cta acg ttg tca 1104Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser355 360 365aac ctg agg ccc gat att aat aag ctt aga agc ctc ata gac acc tac 1152Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr370 375 380ctg tca aaa ggc ccc aga gct ccc ttt atc tgt atc ctc aag gac cct 1200Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro385 390 395 400gtt cat ggt gaa ttt gct cca ggc aat tat cct gca cta tgg agt tac 1248Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr405 410 415gcc atg gga gtc gcc gtc gta cag aac aag gca atg cag cag tac gtc 1296Ala Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val420 425 430aca ggg agg aca tac ctt gat atg gaa atg ttc tta cta gga caa gcc 1344Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala435 440 445gtg gca aag gat gct gaa tcg aag atc agc agt gcc ttg gaa gat gag 1392Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu450 455 460tta gga gtg acg gat aca gcc aag ggg agg ctc aga cat cat ctg gca 1440Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala465 470 475 480aac tag 1446Asn53481PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (G-NPK1) 53Met Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr1 5 10 15Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln20 25 30Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala35 40 45Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser50 55 60Glu Leu Thr Pro Ala Val Thr Ala Asn Ser Ser Ser Val Pro Gly Asp65 70 75 80Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr Phe Ser Ser Arg Arg85 90 95Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala Val Ile Pro Gly Gln100 105 110Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro Ser Val Thr Asp Asp115 120 125Ala Asp Lys Leu Phe Ile Ala Thr Thr

Phe Leu Ala His Ser Leu Asp130 135 140Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe Leu Val Ser Leu Leu145 150 155 160Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu Thr Thr Asn Gly Val165 170 175Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile Glu Lys Asp Pro Lys180 185 190Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr Arg Asp Met Glu Tyr195 200 205Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met Val Asn Lys Ser Pro210 215 220Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro Asp Thr Leu Leu Gln225 230 235 240Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile Ile Val Gln Val Trp245 250 255Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala Gly Leu Arg Lys Gly260 265 270Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp Gly Thr Val Lys Gly275 280 285Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly Ile Gly Ser Val Met290 295 300Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val Glu Thr Leu Val Thr305 310 315 320Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu Glu Lys Asn Ile Gln325 330 335Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu Ala Ser Phe Met Asn340 345 350Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala Ala Leu Thr Leu Ser355 360 365Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser Leu Ile Asp Thr Tyr370 375 380Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys Ile Leu Lys Asp Pro385 390 395 400Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro Ala Leu Trp Ser Tyr405 410 415Ala Met Gly Val Ala Val Val Gln Asn Lys Ala Met Gln Gln Tyr Val420 425 430Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe Leu Leu Gly Gln Ala435 440 445Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser Ala Leu Glu Asp Glu450 455 460Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu Arg His His Leu Ala465 470 475 480Asn541665DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (GG-NPK1) 54atg acc tac aaa tta atc ctg aat ggt aaa acc ttg aaa ggc gaa acc 48Met Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr1 5 10 15act act gaa gcg gtt gat gct gct acc gca gaa aaa gtt ttc aaa cag 96Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln20 25 30tac gct aac gac aac ggt gtt gac ggt gaa tgg acc tac gac gat gcg 144Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala35 40 45act aaa acc ttt acc gtt act gaa aaa ccg gaa gtg atc gat gcg tct 192Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser50 55 60gaa tta acc ccg gcg gtg acc gcg aat tct acc tac aaa tta atc ctg 240Glu Leu Thr Pro Ala Val Thr Ala Asn Ser Thr Tyr Lys Leu Ile Leu65 70 75 80aat ggt aaa acc ttg aaa ggc gaa acc act act gaa gcg gtt gat gct 288Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val Asp Ala85 90 95gct acc gca gaa aaa gtt ttc aaa cag tac gct aac gac aac ggt gtt 336Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val100 105 110gac ggt gaa tgg acc tac gac gat gcg act aaa acc ttt acc gtt act 384Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr115 120 125gaa aaa ccg gaa gtg atc gat gcg tct gaa tta acc ccg gcg gtg acc 432Glu Lys Pro Glu Val Ile Asp Ala Ser Glu Leu Thr Pro Ala Val Thr130 135 140gcg aat tcg agc tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc 480Ala Asn Ser Ser Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser145 150 155 160acc ttc gat aca ttt agc tct agg agg agc gaa agt att aat aag tcg 528Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser165 170 175gga gga ggt gct gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc 576Gly Gly Gly Ala Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe180 185 190gta cta ggc cca agt gtg act gat gat gca gac aag tta ttc att gca 624Val Leu Gly Pro Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala195 200 205act acc ttc cta gct cac tca ttg gac aca gat aag cag cac tct cag 672Thr Thr Phe Leu Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln210 215 220aga gga ggg ttc ctc gtc tct ctg ctt gcc atg gct tac agt agt cca 720Arg Gly Gly Phe Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro225 230 235 240gaa ttg tac ttg aca aca aac gga gta aac gcc gat gtc aaa tat gtg 768Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val245 250 255atc tac aac ata gag aaa gac cct aag agg acg aag aca gac gga ttc 816Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe260 265 270att gtg aag acg aga gat atg gaa tat gag agg acc aca gaa tgg ctg 864Ile Val Lys Thr Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu275 280 285ttt gga cct atg gtc aac aag agc cca ctc ttc cag ggt caa cgg gat 912Phe Gly Pro Met Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp290 295 300gct gca gac cct gac aca ctc ctt caa atc tat ggg tat cct gca tgc 960Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys305 310 315 320cta gga gca ata att gtc caa gtc tgg att gtg ctg gtg aag gcc atc 1008Leu Gly Ala Ile Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile325 330 335aca agc agc gcc ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg 1056Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala340 345 350ttc aga caa gac ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag 1104Phe Arg Gln Asp Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu355 360 365aca gtt gag ggg ata ggc tcg gtt atg aga tct cag caa agc ctt gta 1152Thr Val Glu Gly Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val370 375 380tct ctc atg gtt gag acc ctt gtg act atg aat act gca aga tct gat 1200Ser Leu Met Val Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp385 390 395 400ctc acc aca tta gag aag aac atc cag atc gtt ggg aac tac atc cga 1248Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg405 410 415gat gca ggg ctg gct tcc ttc atg aac act att aaa tat ggg gtg gag 1296Asp Ala Gly Leu Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu420 425 430aca aag atg gca gct cta acg ttg tca aac ctg agg ccc gat att aat 1344Thr Lys Met Ala Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn435 440 445aag ctt aga agc ctc ata gac acc tac ctg tca aaa ggc ccc aga gct 1392Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala450 455 460ccc ttt atc tgt atc ctc aag gac cct gtt cat ggt gaa ttt gct cca 1440Pro Phe Ile Cys Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro465 470 475 480ggc aat tat cct gca cta tgg agt tac gcc atg gga gtc gcc gtc gta 1488Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val485 490 495cag aac aag gca atg cag cag tac gtc aca ggg agg aca tac ctt gat 1536Gln Asn Lys Ala Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp500 505 510atg gaa atg ttc tta cta gga caa gcc gtg gca aag gat gct gaa tcg 1584Met Glu Met Phe Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser515 520 525aag atc agc agt gcc ttg gaa gat gag tta gga gtg acg gat aca gcc 1632Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala530 535 540aag ggg agg ctc aga cat cat ctg gca aac tag 1665Lys Gly Arg Leu Arg His His Leu Ala Asn545 55055554PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (GG-NPK1) 55Met Thr Tyr Lys Leu Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr1 5 10 15Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln20 25 30Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala35 40 45Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser50 55 60Glu Leu Thr Pro Ala Val Thr Ala Asn Ser Thr Tyr Lys Leu Ile Leu65 70 75 80Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val Asp Ala85 90 95Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val100 105 110Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr115 120 125Glu Lys Pro Glu Val Ile Asp Ala Ser Glu Leu Thr Pro Ala Val Thr130 135 140Ala Asn Ser Ser Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser145 150 155 160Thr Phe Asp Thr Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser165 170 175Gly Gly Gly Ala Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe180 185 190Val Leu Gly Pro Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala195 200 205Thr Thr Phe Leu Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln210 215 220Arg Gly Gly Phe Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro225 230 235 240Glu Leu Tyr Leu Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val245 250 255Ile Tyr Asn Ile Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe260 265 270Ile Val Lys Thr Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu275 280 285Phe Gly Pro Met Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp290 295 300Ala Ala Asp Pro Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys305 310 315 320Leu Gly Ala Ile Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile325 330 335Thr Ser Ser Ala Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala340 345 350Phe Arg Gln Asp Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu355 360 365Thr Val Glu Gly Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val370 375 380Ser Leu Met Val Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp385 390 395 400Leu Thr Thr Leu Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg405 410 415Asp Ala Gly Leu Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu420 425 430Thr Lys Met Ala Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn435 440 445Lys Leu Arg Ser Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala450 455 460Pro Phe Ile Cys Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro465 470 475 480Gly Asn Tyr Pro Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val485 490 495Gln Asn Lys Ala Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp500 505 510Met Glu Met Phe Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser515 520 525Lys Ile Ser Ser Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala530 535 540Lys Gly Arg Leu Arg His His Leu Ala Asn545 550561464DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (L-NPK1) 56atg aaa gaa gaa acc ccg gaa acc ccg gaa acc gat agc gaa gaa gaa 48Met Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu1 5 10 15gtg acc atc aaa gcg aac ctg atc ttt gcg aac ggc agc acc cag acc 96Val Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr20 25 30gcg gaa ttt aaa ggt acc ttt gaa aaa gcg acc agc gaa gcg tat gcg 144Ala Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala35 40 45tat gcg gat acc ctg aaa aaa gat aac ggt gaa tat acc gtg gat gtg 192Tyr Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val50 55 60gcg gat aaa ggt tat acc ctg aac att aaa ttt gcg ggt gcg aat tcg 240Ala Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser65 70 75 80agc tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat 288Ser Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp85 90 95aca ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt 336Thr Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly100 105 110gct gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc 384Ala Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly115 120 125cca agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc 432Pro Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe130 135 140cta gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg 480Leu Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly145 150 155 160ttc ctc gtc tct ctg ctt gcc atg gct tac agt agt cca gaa ttg tac 528Phe Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr165 170 175ttg aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac 576Leu Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn180 185 190ata gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag 624Ile Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys195 200 205acg aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct 672Thr Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro210 215 220atg gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac 720Met Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp225 230 235 240cct gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca 768Pro Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala245 250 255ata att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc 816Ile Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser260 265 270gcc ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa 864Ala Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln275 280 285gac ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag 912Asp Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu290 295 300ggg ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg 960Gly Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met305 310 315 320gtt gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca 1008Val Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr325 330 335tta gag aag aac atc cag atc gtt ggg aac tac atc cga gat gca ggg 1056Leu Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly340 345 350ctg gct tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg 1104Leu Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met355 360 365gca gct cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga 1152Ala Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg370 375 380agc ctc ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc 1200Ser Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile385 390 395 400tgt atc ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat 1248Cys Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr405 410 415cct gca cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag 1296Pro Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys420 425 430gca atg cag cag tac gtc aca ggg agg aca tac ctt gat atg gaa atg 1344Ala Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met435 440 445ttc tta cta gga caa gcc gtg gca aag gat gct gaa tcg aag atc agc 1392Phe Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser450 455 460agt gcc ttg gaa gat gag tta gga gtg acg gat

aca gcc aag ggg agg 1440Ser Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg465 470 475 480ctc aga cat cat ctg gca aac tag 1464Leu Arg His His Leu Ala Asn48557487PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (L-NPK1) 57Met Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu1 5 10 15Val Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr20 25 30Ala Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala35 40 45Tyr Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val50 55 60Ala Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser65 70 75 80Ser Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp85 90 95Thr Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly100 105 110Ala Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly115 120 125Pro Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe130 135 140Leu Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly145 150 155 160Phe Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr165 170 175Leu Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn180 185 190Ile Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys195 200 205Thr Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro210 215 220Met Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp225 230 235 240Pro Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala245 250 255Ile Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser260 265 270Ala Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln275 280 285Asp Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu290 295 300Gly Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met305 310 315 320Val Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr325 330 335Leu Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly340 345 350Leu Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met355 360 365Ala Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg370 375 380Ser Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile385 390 395 400Cys Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr405 410 415Pro Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys420 425 430Ala Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met435 440 445Phe Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser450 455 460Ser Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg465 470 475 480Leu Arg His His Leu Ala Asn485581701DNAArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (LL-NPK1) 58atg aaa gaa gaa acc ccg gaa acc ccg gaa acc gat agc gaa gaa gaa 48Met Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu1 5 10 15gtg acc atc aaa gcg aac ctg atc ttt gcg aac ggc agc acc cag acc 96Val Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr20 25 30gcg gaa ttt aaa ggt acc ttt gaa aaa gcg acc agc gaa gcg tat gcg 144Ala Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala35 40 45tat gcg gat acc ctg aaa aaa gat aac ggt gaa tat acc gtg gat gtg 192Tyr Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val50 55 60gcg gat aaa ggt tat acc ctg aac att aaa ttt gcg ggt gcg aat tct 240Ala Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser65 70 75 80aaa gaa gaa acc ccg gaa acc ccg gaa acc gat agc gaa gaa gaa gtg 288Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu Val85 90 95acc atc aaa gcg aac ctg atc ttt gcg aac ggc agc acc cag acc gcg 336Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr Ala100 105 110gaa ttt aaa ggt acc ttt gaa aaa gcg acc agc gaa gcg tat gcg tat 384Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala Tyr115 120 125gcg gat acc ctg aaa aaa gat aac ggt gaa tat acc gtg gat gtg gcg 432Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val Ala130 135 140gat aaa ggt tat acc ctg aac att aaa ttt gcg ggt gcg aat tcg agc 480Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser Ser145 150 155 160tcg gta ccc ggg gat ccg atg gcc ggg ttg ttg agc acc ttc gat aca 528Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr165 170 175ttt agc tct agg agg agc gaa agt att aat aag tcg gga gga ggt gct 576Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala180 185 190gtt atc ccc ggc cag agg agc aca gtc tca gtg ttc gta cta ggc cca 624Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro195 200 205agt gtg act gat gat gca gac aag tta ttc att gca act acc ttc cta 672Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu210 215 220gct cac tca ttg gac aca gat aag cag cac tct cag aga gga ggg ttc 720Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe225 230 235 240ctc gtc tct ctg ctt gcc atg gct tac agt agt cca gaa ttg tac ttg 768Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu245 250 255aca aca aac gga gta aac gcc gat gtc aaa tat gtg atc tac aac ata 816Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile260 265 270gag aaa gac cct aag agg acg aag aca gac gga ttc att gtg aag acg 864Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr275 280 285aga gat atg gaa tat gag agg acc aca gaa tgg ctg ttt gga cct atg 912Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met290 295 300gtc aac aag agc cca ctc ttc cag ggt caa cgg gat gct gca gac cct 960Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro305 310 315 320gac aca ctc ctt caa atc tat ggg tat cct gca tgc cta gga gca ata 1008Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile325 330 335att gtc caa gtc tgg att gtg ctg gtg aag gcc atc aca agc agc gcc 1056Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala340 345 350ggc tta agg aaa ggg ttc ttc aac agg tta gag gcg ttc aga caa gac 1104Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp355 360 365ggc acc gtg aaa ggt gcc tta gtt ttc act ggg gag aca gtt gag ggg 1152Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly370 375 380ata ggc tcg gtt atg aga tct cag caa agc ctt gta tct ctc atg gtt 1200Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val385 390 395 400gag acc ctt gtg act atg aat act gca aga tct gat ctc acc aca tta 1248Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu405 410 415gag aag aac atc cag atc gtt ggg aac tac atc cga gat gca ggg ctg 1296Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu420 425 430gct tcc ttc atg aac act att aaa tat ggg gtg gag aca aag atg gca 1344Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala435 440 445gct cta acg ttg tca aac ctg agg ccc gat att aat aag ctt aga agc 1392Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser450 455 460ctc ata gac acc tac ctg tca aaa ggc ccc aga gct ccc ttt atc tgt 1440Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys465 470 475 480atc ctc aag gac cct gtt cat ggt gaa ttt gct cca ggc aat tat cct 1488Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro485 490 495gca cta tgg agt tac gcc atg gga gtc gcc gtc gta cag aac aag gca 1536Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala500 505 510atg cag cag tac gtc aca ggg agg aca tac ctt gat atg gaa atg ttc 1584Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe515 520 525tta cta gga caa gcc gtg gca aag gat gct gaa tcg aag atc agc agt 1632Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser530 535 540gcc ttg gaa gat gag tta gga gtg acg gat aca gcc aag ggg agg ctc 1680Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu545 550 555 560aga cat cat ctg gca aac tag 1701Arg His His Leu Ala Asn56559566PRTArtificialFusion protein includes antibody binding amino acid sequence and Sendai virus nucleocapsid protein (LL-NPK1) 59Met Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu1 5 10 15Val Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr20 25 30Ala Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala35 40 45Tyr Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val50 55 60Ala Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser65 70 75 80Lys Glu Glu Thr Pro Glu Thr Pro Glu Thr Asp Ser Glu Glu Glu Val85 90 95Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gln Thr Ala100 105 110Glu Phe Lys Gly Thr Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala Tyr115 120 125Ala Asp Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val Ala130 135 140Asp Lys Gly Tyr Thr Leu Asn Ile Lys Phe Ala Gly Ala Asn Ser Ser145 150 155 160Ser Val Pro Gly Asp Pro Met Ala Gly Leu Leu Ser Thr Phe Asp Thr165 170 175Phe Ser Ser Arg Arg Ser Glu Ser Ile Asn Lys Ser Gly Gly Gly Ala180 185 190Val Ile Pro Gly Gln Arg Ser Thr Val Ser Val Phe Val Leu Gly Pro195 200 205Ser Val Thr Asp Asp Ala Asp Lys Leu Phe Ile Ala Thr Thr Phe Leu210 215 220Ala His Ser Leu Asp Thr Asp Lys Gln His Ser Gln Arg Gly Gly Phe225 230 235 240Leu Val Ser Leu Leu Ala Met Ala Tyr Ser Ser Pro Glu Leu Tyr Leu245 250 255Thr Thr Asn Gly Val Asn Ala Asp Val Lys Tyr Val Ile Tyr Asn Ile260 265 270Glu Lys Asp Pro Lys Arg Thr Lys Thr Asp Gly Phe Ile Val Lys Thr275 280 285Arg Asp Met Glu Tyr Glu Arg Thr Thr Glu Trp Leu Phe Gly Pro Met290 295 300Val Asn Lys Ser Pro Leu Phe Gln Gly Gln Arg Asp Ala Ala Asp Pro305 310 315 320Asp Thr Leu Leu Gln Ile Tyr Gly Tyr Pro Ala Cys Leu Gly Ala Ile325 330 335Ile Val Gln Val Trp Ile Val Leu Val Lys Ala Ile Thr Ser Ser Ala340 345 350Gly Leu Arg Lys Gly Phe Phe Asn Arg Leu Glu Ala Phe Arg Gln Asp355 360 365Gly Thr Val Lys Gly Ala Leu Val Phe Thr Gly Glu Thr Val Glu Gly370 375 380Ile Gly Ser Val Met Arg Ser Gln Gln Ser Leu Val Ser Leu Met Val385 390 395 400Glu Thr Leu Val Thr Met Asn Thr Ala Arg Ser Asp Leu Thr Thr Leu405 410 415Glu Lys Asn Ile Gln Ile Val Gly Asn Tyr Ile Arg Asp Ala Gly Leu420 425 430Ala Ser Phe Met Asn Thr Ile Lys Tyr Gly Val Glu Thr Lys Met Ala435 440 445Ala Leu Thr Leu Ser Asn Leu Arg Pro Asp Ile Asn Lys Leu Arg Ser450 455 460Leu Ile Asp Thr Tyr Leu Ser Lys Gly Pro Arg Ala Pro Phe Ile Cys465 470 475 480Ile Leu Lys Asp Pro Val His Gly Glu Phe Ala Pro Gly Asn Tyr Pro485 490 495Ala Leu Trp Ser Tyr Ala Met Gly Val Ala Val Val Gln Asn Lys Ala500 505 510Met Gln Gln Tyr Val Thr Gly Arg Thr Tyr Leu Asp Met Glu Met Phe515 520 525Leu Leu Gly Gln Ala Val Ala Lys Asp Ala Glu Ser Lys Ile Ser Ser530 535 540Ala Leu Glu Asp Glu Leu Gly Val Thr Asp Thr Ala Lys Gly Arg Leu545 550 555 560Arg His His Leu Ala Asn565

Claims

1. A protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell.

2. The protein according to claim 1, wherein the protein comprising said polypeptide (a) in combination with the polypeptide (b) is a fusion protein.

3. The protein according to claim 1 or 2, wherein said polypeptide (a) is a polypeptide having an affinity for one or more components existing in the inner space of an envelope.

4. The protein according to claim 1 or 2, wherein said polypeptide (a) is(1) a polypeptide of an amino acid sequence of SEQ ID NO: 2,(2) a polypeptide having an amino acid sequence substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or(3) a peptide fragment (partial peptide) thereof.

5. The protein according to claim 1 or 2, wherein said polypeptide (b) is an antibody binding polypeptide.

6. The protein according to claim 5, wherein said antibody binding polypeptide is a polypeptide that can bind to an antibody Fc region or kappa (K) light chain.

7. The protein according to claim 5, wherein said antibody binding polypeptide is(1) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51,(2) a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence (1), or(3) a peptide fragment (partial peptide) thereof.

8. A DNA encoding a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components and a polypeptide capable of binding to an antibody wherein said fusion protein is a polypeptide selected from the group consisting of:(1) a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof,(2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and(3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

9. An envelope virus or inactivated envelope virus containing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell.

10. The envelope virus or inactivated envelope virus according to claim 9, wherein said virus contains a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components and an antibody-binding polypeptide wherein said fusion protein is a polypeptide selected from the group consisting of:(1) a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof,(2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and(3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

11. An envelope virus or inactivated envelope virus containing a complex constituted of (i) a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, and (ii) one or more foreign substances.

12. The envelope virus or inactivated envelope virus according to claim 11, wherein said foreign substance is an antibody.

13. The envelope virus or inactivated envelope virus according to claim 12, wherein said virus contains a complex constituted of a fusion protein consisting of a polypeptide having an affinity for one or more envelope viral components, fused to an antibody binding polypeptide, andan antibody,wherein said fusion protein is a polypeptide selected from the group consisting of:(1) a fusion polypeptide consisting of a polypeptide of an amino acid sequence of SEQ ID NO: 2, a polypeptide substantially equivalent to the amino acid sequence of SEQ ID NO: 2, or a peptide fragment thereof, fused with a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 49 and 51, a polypeptide having an amino acid sequence substantially equivalent to the aforementioned amino acid sequence of SEQ ID NO: 4, 49 or 51, or a peptide fragment thereof,(2) a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59, and(3) a polypeptide having an amino acid sequence substantially equivalent to a polypeptide of an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 13, 55 and 59.

14. A process for preparing an envelope virus or inactivated envelope virus containing a foreign substance within an envelope, which comprises the steps consisting of(1) mixing an envelope virus or inactivated envelope virus with a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell,(2) subjecting the resultant mixture from the above step (1), to a treatment affecting the permeability of envelopes, and(3) mixing the resultant product from the above step (2), with one or more foreign substances.

15. A process for preparing an envelope virus or inactivated envelope virus containing a foreign substance within an envelope, which comprises the steps consisting of(1) mixing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, with one or more foreign substances to form a complex,(2) mixing the resultant mixture from the above step (1), with an envelope virus or inactivated envelope virus, and(3) subjecting the resultant mixture from the above step (2), to a treatment affecting the permeability of envelopes.

16. The process according to claim 14 or 15, wherein the protein comprising said polypeptide (a) in combination with the polypeptide (b) is a fusion protein.

17. The process according to claim 14 or 15, wherein said foreign substance is an antibody.

18. A method for introducing one or more foreign substances into a cell with an envelope virus or inactivated envelope virus, which comprises the steps consisting of(1) mixing an envelope virus or inactivated envelope virus with a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell,(2) subjecting the resultant mixture from the above step (1), to a treatment affecting the permeability of envelopes,(3) mixing the resultant product from the above step (2) with one or more foreign substances, and(4) contacting the resulting foreign substance-containing envelope virus or inactivated envelope virus from the above step (3), with one or more cells.

19. A method for introducing one or more foreign substances into a cell with an envelope virus or inactivated envelope virus, which comprises the steps consisting of(1) mixing a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, with one or more foreign substances to form a complex,(2) mixing the resultant mixture from the above step (1), with an envelope virus or inactivated envelope virus,(3) subjecting the resultant mixture from the above step (2), to a treatment affecting the permeability of envelopes and(4) contacting the resulting foreign substance-containing envelope virus or inactivated envelope virus from the above step (3), with one or more cells.

20. The process according to claim 18 or 19, wherein the protein comprising said polypeptide (a) in combination with the polypeptide (b) is a fusion protein.

21. The process according to claim 18 or 19, wherein said foreign substance is an antibody.

22. A complex constituted of (i) a protein comprising (a) a polypeptide having an affinity for one or more envelope viral components in combination with (b) a polypeptide capable of binding to one or more foreign substances to be introduced into a cell, and (ii) one or more foreign substances to be introduced into one or more cells.